Document:

Master Confirmation

 Exhibit 10.61 
 EXECUTION COPY 
 GOLDMAN, SACHS & CO. | 85 BROAD STREET | NEW YORK, NEW YORK 10004 |
TEL: 212-902-1000 
 Opening Transaction 
  

			
	To:  	  	 Gilead Sciences, Inc.
 333 Lakeside Drive

Foster City, CA 94404

		
	 A/C:
	  	028820868
		
	 From:
	  	Goldman, Sachs & Co.
		
	 Re:
	  	Collared Accelerated Stock Buyback
		
	 Ref. No:
	  	As provided in the Supplemental Confirmation
		
	 Date:
	  	February 29, 2008

 This master confirmation (this “Master Confirmation”), dated as of
February 29, 2008 is intended to set forth certain terms and provisions of certain Transactions (each, a “Transaction”) entered into from time to time between Goldman, Sachs & Co. (“GS&Co.”) and
Gilead Sciences, Inc. (“Counterparty”). This Master Confirmation, taken alone, is neither a commitment by either party to enter into any Transaction nor evidence of a Transaction. The additional terms of any particular Transaction
shall be set forth in (i) a Supplemental Confirmation in the form of Schedule A hereto (a “Supplemental Confirmation”), which shall reference this Master Confirmation and supplement, form a part of, and be subject to this
Master Confirmation and (ii) a Trade Notification in the form of Schedule B hereto (a “Trade Notification”), which shall reference the relevant Supplemental Confirmation and supplement, form a part of, and be subject to such
Supplemental Confirmation. This Master Confirmation, each Supplemental Confirmation and the related Trade Notification together shall constitute a “Confirmation” as referred to in the Agreement specified below. 
 The definitions and provisions contained in the 2002 ISDA Equity Derivatives Definitions (the “Equity Definitions”), as published by the
International Swaps and Derivatives Association, Inc., are incorporated into this Master Confirmation. This Master Confirmation, each Supplemental Confirmation and the related Trade Notification evidence a complete binding agreement between
Counterparty and GS&Co. as to the subject matter and terms of each Transaction to which this Master Confirmation, such Supplemental Confirmation and Trade Notification relate and shall supersede all prior or contemporaneous written or oral
communications with respect thereto. 
 This Master Confirmation, each Supplemental Confirmation and each Trade Notification supplement, form
a part of, and are subject to an agreement in the form of the 1992 ISDA Master Agreement (Multicurrency-Cross Border) (the “Agreement”) as if GS&Co. and Counterparty had executed the Agreement on the date of this Master
Confirmation (but without any Schedule except for (i) the election of Loss and Second Method, New York law (without reference to its choice of laws doctrine other than Title 14 of Article 5 of the New York General Obligations Law) as the
governing law and US Dollars (“USD”) as the Termination Currency, (ii) the election that subparagraph (ii) of Section 2(c) will not apply to the Transactions, (iii) the replacement of the word “third”
in the last line of Section 5(a)(i) with the word “first” and (iv) the election that the “Cross Default” provisions of Section 5(a)(vi) shall apply to GS&Co. and Counterparty, in each case with a
“Threshold Amount” of USD 100 million; provided that the phrase “or becoming capable at such time of being declared” shall be deleted from clause (1) of such Section 5(a)(vi)). 
 The Transactions shall be the sole Transactions under the Agreement. If there exists any ISDA Master Agreement between GS&Co. and Counterparty or any
confirmation or other agreement between GS&Co. and Counterparty pursuant to which an ISDA Master Agreement is deemed to exist between GS&Co. and Counterparty, then notwithstanding anything to the contrary in such ISDA Master Agreement, such
confirmation or agreement or any other agreement to which GS&Co. and Counterparty are parties, the Transactions shall not be considered Transactions under, or otherwise governed by, such existing or deemed ISDA Master Agreement. 

 All provisions contained or incorporated by reference in the Agreement shall govern this Master
Confirmation, each Supplemental Confirmation and each Trade Notification except as expressly modified herein or in the related Supplemental Confirmation. 
 If, in relation to any Transaction to which this Master Confirmation, a Supplemental Confirmation and a Trade Notification relate, there is any inconsistency between the Agreement, this Master Confirmation, any
Supplemental Confirmation, any Trade Notification and the Equity Definitions, the following will prevail for purposes of such Transaction in the order of precedence indicated: (i) such Trade Notification, (ii) such Supplemental
Confirmation; (iii) this Master Confirmation; (iv) the Agreement; and (v) the Equity Definitions. 
 1. Each Transaction constitutes a Share
Forward Transaction for the purposes of the Equity Definitions. Set forth below are the terms and conditions that, together with the terms and conditions set forth in the Supplemental Confirmation and Trade Notification relating to any Transaction,
shall govern such Transaction. 
 General Terms: 
  

			
	 Trade Date:
	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	 Buyer:
	  	Counterparty
		
	 Seller:
	  	GS&Co.
		
	 Shares:
	  	Common stock, par value $0.001 per share, of Counterparty (Ticker: GILD)
		
	 Exchange:
	  	NASDAQ
		
	 Related Exchange(s):
	  	All Exchanges.
		
	Prepayment\Variable Obligation:	  	

Applicable
		
	 Prepayment Amount:
	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	 Prepayment Date:
	  	For each Transaction, as set forth in the related Supplemental Confirmation.

 Valuation: 
  

			
	Hedge Period:	  	The period from and including the first Exchange Business Day following the Trade Date to and including the Hedge Completion Date.
		
	Hedge Completion Date:	  	For each Transaction, as set forth in the related Trade Notification, to be the Exchange Business Day on which GS&Co. finishes establishing its initial Hedge Positions in respect of such
Transaction, as determined by GS&Co. in its sole discretion, but in no event later than the Hedge Period End Date.
		
	Hedge Period End Date:	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	Hedge Period Reference Price:	  	For each Transaction, as set forth in the related Trade Notification, to be the average of the VWAP Prices for the Exchange Business Days in the Hedge Period, subject to “Valuation
Disruption” below.

  

 2 

			
	VWAP Price:	  	For any Exchange Business Day, as determined by the Calculation Agent based on the NASDAQ 10b-18 Volume Weighted Average Price per Share for the regular trading session (including any
extensions thereof) of the Exchange on such Exchange Business Day (without regard to pre-open or after hours trading outside of such regular trading session for such Exchange Business Day), as published by Bloomberg at 4:15 p.m. New York time (or 15
minutes following the end of any extension of the regular trading session) on such Exchange Business Day, on Bloomberg page “GILD.Q <Equity> AQR_SEC” (or any successor thereto), or if such price is not so reported on such Exchange
Business Day for any reason or is, in the Calculation Agent’s reasonable discretion, erroneous, such VWAP Price shall be as reasonably determined by the Calculation Agent. For purposes of calculating the VWAP Price, the Calculation Agent will
include only those trades that are reported during the period of time during which Counterparty could purchase its own shares under Rule 10b-18(b)(2) and are effected pursuant to the conditions of Rule 10b-18(b)(3), each under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) (such trades, “Rule 10b-18 eligible transactions”).
		
	Forward Price:	  	The average of the VWAP Prices for the Exchange Business Days in the Calculation Period, subject to “Valuation Disruption” below.
	 Forward Price
	  	
	Adjustment Amount:	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	Calculation Period:	  	The period from and including the Calculation Period Start Date to and including the Termination Date.
		
	Calculation Period Start Date:	  	For each Transaction, as set forth in the related Trade Notification, to be the first Exchange Business Day immediately following the Hedge Completion Date.
		
	Termination Date:	  	The Scheduled Termination Date; provided that GS&Co. shall have the right to designate any Exchange Business Day on or after the First Acceleration Date to be the Termination Date
by delivering telephonic notice to Counterparty, to be confirmed by email, of any such designation no later than prior to the open of trading on the Exchange on the Exchange Business Day immediately following the Termination Date.
		
	Scheduled Termination Date:	  	For each Transaction, as set forth in the related Supplemental Confirmation, subject to postponement as provided in “Valuation Disruption” below.
		
	First Acceleration Date:	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	Valuation Disruption:	  	The definition of “Market Disruption Event” in Section 6.3(a) of the Equity Definitions is hereby amended by deleting the words “at any time during the one-hour period that
ends at the relevant Valuation Time, Latest Exercise Time, Knock-in Valuation Time or Knock-out Valuation Time, as the case may be” and inserting the words “at any time on any Scheduled Trading Day during the Hedge Period, Calculation
Period or Settlement Valuation Period” after the word “material,” in the third line thereof.
		
		  	Section 6.3(d) of the Equity Definitions is hereby amended by deleting the remainder of the provision following the term “Scheduled Closing Time” in the fourth line
thereof.
		
		  	Notwithstanding anything to the contrary in the Equity Definitions, to the extent that a Disrupted Day occurs (i) in the Hedge Period or the Calculation Period, the Calculation Agent may, in
its good faith and commercially reasonable

  

 3 

			
		  	discretion, postpone either or both of the Hedge Period End Date and/or the Scheduled Termination Date, or (ii) in the Settlement Valuation Period, the Calculation Agent may extend the
Settlement Valuation Period. If any such Disrupted Day is a Disrupted Day because of a Market Disruption Event (or a deemed Market Disruption Event as provided herein), the Calculation Agent shall determine whether (i) such Disrupted Day is a
Disrupted Day in full, in which case the VWAP Price for such Disrupted Day shall not be included for purposes of determining the Hedge Period Reference Price, the Forward Price or the Settlement Price, as the case may be, or (ii) such Disrupted Day
is a Disrupted Day only in part, in which case the VWAP Price for such Disrupted Day shall be determined by the Calculation Agent based on Rule 10b-18 eligible transactions in the Shares on such Disrupted Day effected before the relevant Market
Disruption Event occurred and/or after the relevant Market Disruption Event ended, and the weighting of the VWAP Price for the relevant Exchange Business Days during the Hedge Period, the Calculation Period or the Settlement Valuation Period, as the
case may be, shall be adjusted in a commercially reasonable manner by the Calculation Agent for purposes of determining the Hedge Period Reference Price, the Forward Price or the Settlement Price, as the case may be, with such adjustments based on,
among other factors, the duration of any Market Disruption Event and the volume, historical trading patterns and price of the Shares. Any Scheduled Trading Day on which the Exchange is scheduled to close prior to its normal close of trading shall be
deemed to be a Disrupted Day in full.
		
		  	If a Disrupted Day occurs during the Hedge Period, the Calculation Period or the Settlement Valuation Period, as the case may be, and each of the nine immediately following Scheduled Trading
Days is a Disrupted Day, then the Calculation Agent, in its good faith and commercially reasonable discretion, may deem such ninth Scheduled Trading Day to be an Exchange Business Day that is not a Disrupted Day and determine the VWAP Price for such
ninth Scheduled Trading Day using its good faith estimate of the value of the Shares on such ninth Scheduled Trading Day based on the volume, historical trading patterns and price of the Shares and such other factors as it deems
appropriate.
		
	Settlement Terms:	  	
		
	 Physical Settlement:
	  	Applicable to GS&Co.; provided that GS&Co. does not, and shall not, make the agreement or the representations set forth in Section 9.11 of the Equity Definitions related to the
restrictions imposed by applicable securities laws with respect to any Shares delivered by GS&Co. to Counterparty under any Transaction. The Counterparty Settlement Provisions are set forth in Annex A hereto.
	 Number of Shares
	  	
	 to be Delivered:
	  	A number of Shares equal to (a) the Prepayment Amount divided by (b)(i) the Forward Price minus (ii) the Forward Price Adjustment Amount; provided that the Number of
Shares to be Delivered shall not be less than the Minimum Shares and not greater than the Maximum Shares. The Number of Shares to be Delivered on the Settlement Date shall be reduced, but not below zero, by any Shares delivered pursuant to the
Initial Share Delivery and the Minimum Share Delivery described below.
		
	 Excess Dividend Amount:
	  	For the avoidance of doubt, all references to the Excess Dividend Amount shall be deleted from Section 9.2(a)(iii) of the Equity Definitions.
		
	 Settlement Date:
	  	The date that is one Settlement Cycle immediately following the Termination Date.

  

 4 

			
	 Settlement Currency:
	  	USD
		
	 Initial Share Delivery:
	  	GS&Co. shall deliver a number of Shares equal to the Initial Shares to Counterparty on the Initial Share Delivery Date in accordance with Section 9.4 of the Equity Definitions, with the
Initial Share Delivery Date deemed to be a “Settlement Date” for purposes of such Section 9.4.
		
	 Initial Share Delivery Date:
	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	 Initial Shares:
	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	 Minimum Share Delivery:
	  	GS&Co. shall deliver a number of Shares equal to the excess, if any, of the Minimum Shares over the Initial Shares on the Minimum Share Delivery Date in accordance with Section 9.4 of the
Equity Definitions, with the Minimum Share Delivery Date deemed to be a “Settlement Date” for purposes of such Section 9.4.
		
	 Minimum Share Delivery Date:
	  	The date one Settlement Cycle immediately following the Hedge Completion Date.
		
	 Minimum Shares:
	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	 Maximum Shares:
	  	For each Transaction, as set forth in the related Supplemental Confirmation.
		
	Share Adjustments:	  	
		
	 Potential Adjustment Event:
	  	Notwithstanding anything to the contrary in Section 11.2(e) of the Equity Definitions, an Extraordinary Dividend shall not constitute a Potential Adjustment Event.
		
		  	It shall constitute an additional Potential Adjustment Event if the Scheduled Termination Date for any Transaction is postponed pursuant to “Valuation Disruption” above, in which
case the Calculation Agent may, in its commercially reasonable discretion, adjust any relevant terms of any such Transaction as necessary to preserve as nearly as practicable the fair value of such Transaction to GS&Co. prior to such
postponement.
		
	 Extraordinary Dividend:
	  	Any dividend or distribution on the Shares (other than any dividend or distribution of the type described in Section 11.2(e)(i) or Section 11.2(e)(ii)(A) or (B) of the Equity Definitions)
that has an ex-dividend date occurring during the Relevant Dividend Period (as defined below). For the avoidance of doubt, the Calculation Agent shall not make any adjustments to account for changes in extraordinary dividends under any circumstances
under this Master Confirmation.
		
	 Method of Adjustment:
	  	Calculation Agent Adjustment
		
	Extraordinary Events:	  	
		
	 Consequences of Merger Events:
	  	
		
	 (a) Share-for-Share:
	  	 Modified Calculation Agent Adjustment

  

 5 

			
	 (b) Share-for-Other:
	  	 Cancellation and Payment

		
	 (c) Share-for-Combined:
	  	 Component Adjustment

		
	Tender Offer:	  	Applicable; provided that (i) Section 12.1(l) of the Equity Definitions shall be amended (x) by deleting the parenthetical in the fifth line thereof, (y) by replacing “that”
in the fifth line thereof with “whether or not such announcement” and (z) by adding immediately after the words “Tender Offer” in the fifth line thereof “, and any publicly announced change or amendment to such an
announcement (including the announcement of an abandonment of such intention)” and (ii) Sections 12.3(a) and 12.3(d) of the Equity Definitions shall each be amended by replacing each occurrence of the words “Tender Offer Date” by
“Announcement Date.”
		
	Consequences of Tender Offers:	  	
		
	 (a) Share-for-Share:
	  	 Modified Calculation Agent Adjustment or Cancellation and Payment, at the election of GS&Co.

		
	 (b) Share-for-Other:
	  	 Modified Calculation Agent Adjustment or Cancellation and Payment, at the election of GS&Co.

		
	 (c) Share-for-Combined:
	  	 Modified Calculation Agent Adjustment or Cancellation and Payment, at the election of GS&Co.

		
	Nationalization, Insolvency or Delisting:	  	Cancellation and Payment; provided that in addition to the provisions of Section 12.6(a)(iii) of the Equity Definitions, it shall also constitute a Delisting if the Exchange is located
in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, the American Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective
successors); if the Shares are immediately re-listed, re-traded or re-quoted on any such exchange or quotation system, such exchange or quotation system shall be deemed to be the Exchange.
		
	Additional Disruption Events:	  	
		
	 (a) Change in Law:
	  	 Applicable; provided that Section 12.9(a)(ii) of the Equity Definitions shall be amended by deleting clause (Y) in its entirety.

		
	 (b) Failure to Deliver:
	  	 Applicable

		
	 (c) Insolvency Filing:
	  	 Applicable

		
	 Determining Party:
	  	 GS&Co.

		
	Additional Termination Event(s):	  	Notwithstanding anything to the contrary in the Equity Definitions, if, as a result of an Extraordinary Event, any Transaction would be cancelled or terminated (whether in whole or in part)
pursuant to Article 12 of the Equity Definitions, an Additional Termination Event (with such terminated Transaction(s) (or portions thereof) being the Affected Transaction(s) and Counterparty being the sole Affected Party (provided that, solely in
the case of a Failure to Deliver, GS&Co. shall be the sole Affected Party)) shall be deemed to occur, and, in lieu of Sections 12.7, 12.8 and 12.9 of the Equity Definitions, Section 6 of the Agreement shall apply to such Affected Transaction(s).

  

 6 

			
		  	The declaration by the Issuer of any Extraordinary Dividend will constitute an Additional Termination Event, with Counterparty as the sole Affected Party and all Transactions hereunder as the
Affected Transactions.
		
	 Relevant Dividend Period:
	  	The period from and including the first day of the Hedge Period to and including the later of the last day of the Relevant Period (as defined in Section 4(f) of this Master Confirmation) and
the last day of the Settlement Valuation Period, if any.
		
	Non-Reliance/Agreements and Acknowledgements Regarding Hedging Activities/Additional Acknowledgements:	  	Applicable
		
	 Transfer:
	  	Notwithstanding anything to the contrary in the Agreement, GS&Co. may assign, transfer and set over all rights, title and interest, powers, privileges and remedies of GS&Co. under any
Transaction, in whole or in part, to an affiliate of GS&Co. (the “Assignee”) without the consent of Counterparty; provided that (i) Counterparty will not, as a result of such transfer, be required to pay to the Assignee
an amount in respect of an Indemnifiable Tax under Section 2(d)(i)(4) of the Agreement, (ii) the Assignee will not, as a result of such transfer, be required to withhold or deduct any amount on account of a Tax under Section 2(d)(i) of the
Agreement, unless the Assignee would be required to make additional payments pursuant to Section 2(d)(i)(4) of the Agreement corresponding to such excess, in which case, Counterparty shall have the right to elect that GS&Co. deliver Shares in
lieu of making any such additional payments in cash as if the amount required to be so paid were a Payment Amount in accordance with Section 14 of this Master Confirmation, (iii) no Event of Default, Potential Event of Default or Termination Event
with respect to the Assignee shall exist after giving effect to such assignment, transfer or set over, (iv) the obligations of the Assignee are fully and unconditionally guaranteed by The Goldman Sachs Group, Inc., (v) at the time of the Transfer,
the transferred Transaction represents a legal, valid and binding obligation of the Assignee and (vi) immediately after such transfer, the Counterparty shall receive notice thereof.
		
	 GS&Co. Payment Instructions:
	  	 Chase Manhattan Bank New York
 For A/C Goldman, Sachs
& Co.
 A/C #930-1-011483
 ABA:
021-000021

		
	Counterparty’s Contact Details for Purpose of Giving Notice:	  	To be provided by Counterparty
		
	GS&Co.’s Contact Details for Purpose of Giving Notice:	  	 Telephone No.: (212) 902-8996
 Facsimile No.: (212)
902-0112
 Attention: Equity Operations: Options and Derivatives

		
		  	 With a copy to:
 Tracey McCabe
 Equity Capital Markets
 One New York Plaza New York, NY 10004
 Telephone No.: (212) 357-0428
 Facsimile No.: (212)
902-3000

  

 7 

 2. Calculation Agent. GS&Co. 
 3. Additional Mutual Representations, Warranties and Covenants of Each Party. In addition to the representations, warranties and covenants in the Agreement, each party represents, warrants and covenants to the other party that:

 (a) Eligible Contract Participant. It is an “eligible contract participant”, as defined in the U.S. Commodity Exchange
Act (as amended), and is entering into each Transaction hereunder as principal (and not as agent or in any other capacity, fiduciary or otherwise) and not for the benefit of any third party. 
 (b) Accredited Investor. Each party acknowledges that the offer and sale of each Transaction to it is intended to be exempt from registration
under the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 4(2) thereof. Accordingly, each party represents and warrants to the other that (i) it has the financial ability to bear the
economic risk of its investment in each Transaction and is able to bear a total loss of its investment, (ii) it is an “accredited investor” as that term is defined under Regulation D under the Securities Act and (iii) the
disposition of each Transaction is restricted under this Master Confirmation, the Securities Act and state securities laws. 
 4. Additional
Representations, Warranties and Covenants of Counterparty. In addition to the representations, warranties and covenants in the Agreement, Counterparty represents, warrants and covenants to GS&Co. that: 
 (a) It is not entering into any Transaction (i) on the basis of, and is, as of the Trade Date for any Transaction, not aware of, any material
non-public information with respect to the Shares (ii) in anticipation of, in connection with, or to facilitate, a distribution of its securities, a self tender offer or a third-party tender offer or (iii) to create actual or apparent
trading activity in the Shares (or any security convertible into or exchangeable for the Shares) or to raise or depress or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for the Shares). 
 (b) Each Transaction is being entered into pursuant to a publicly disclosed Share buy-back program and its Board of Directors has approved the use of
derivatives to effect the Share buy-back program. 
 (c) It intends that each Transaction qualifies as an equity instrument for purposes of
EITF Issue No. 00-19 as in effect on the Trade Date. Notwithstanding the foregoing and without limiting the generality of Section 13.1 of the Equity Definitions, it acknowledges that neither GS&Co. nor any of its affiliates is making any
representations or warranties or taking any position or expressing any view with respect to the treatment of any Transaction under any accounting standards including FASB Statements 128, 133 as amended, or 149, 150, EITF 00-19, 01-6 or EITF 03-6 (or
any successor issue statements) or under the Financial Accounting Standards Board’s Liabilities & Equity Project. 
 (d) As of
(i) the date hereof and (ii) the Trade Date for each Transaction hereunder, Counterparty is in compliance with its reporting obligations under the Exchange Act and its most recent Annual Report on Form 10-K, together with all reports
subsequently filed by it pursuant to the Exchange Act, taken together and as amended and supplemented to the date of this representation, do not, as of their respective filing dates, contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; 
 (e) Counterparty is aware of its reporting obligations as required under Regulation S-K under the Exchange Act in respect of the Transactions hereunder. 
 (f) The Shares are not, and Counterparty will not cause the Shares to be, subject to a “restricted period” (as defined in Regulation M
promulgated under the Exchange Act) at any time during any Regulation M Period (as defined below) for any Transaction unless Counterparty has provided written notice to GS&Co. of such restricted period not later than the Scheduled Trading Day
immediately preceding the first day of such “restricted period”. Counterparty acknowledges that any such notice may cause a Disrupted Day to occur pursuant to Section 5 below. Accordingly, Counterparty acknowledges that its delivery
of such notice must comply with the standards set forth in Section 6(c) below. “Regulation M Period” means, for any Transaction, (i) the Relevant Period (as defined 

  

 8 

 
below) and (ii) the Settlement Valuation Period, if any, for such Transaction. “Relevant Period” means, for any Transaction, the period
commencing on the first day of the Hedge Period for such Transaction and ending on the earlier of (i) the Scheduled Termination Date and (ii) the last Additional Relevant Day (as specified in the related Supplemental Confirmation) for such
Transaction, or such earlier day as elected by GS&Co. and communicated to Counterparty on such day (or, if later, the First Acceleration Date without regard to any acceleration thereof pursuant to “Special Provisions for Friendly
Transaction Announcements” below). 
 (g) As of the Trade Date and the Prepayment Date for each Transaction, Counterparty is not
“insolvent” (as such term is defined under Section 101(32) of the U.S. Bankruptcy Code (Title 11 of the United States Code) (the “Bankruptcy Code”)) and Counterparty would be able to purchase a number of Shares with a
value equal to the Prepayment Amount in compliance with the laws of the jurisdiction of Counterparty’s incorporation. 
 (h)
Counterparty is not and, after giving effect to any Transaction, will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended. 
 (i) Counterparty has not and will not enter into agreements similar to the Transactions described herein where any initial hedge period, calculation
period, relevant period or settlement valuation period (each however defined) in such other transaction will overlap at any time (including as a result of extensions in such initial hedge period, calculation period, relevant period or settlement
valuation period as provided in the relevant agreements) with any Relevant Period or, if applicable, any Settlement Valuation Period under this Master Confirmation. In the event that the initial hedge period, relevant period, calculation period or
settlement valuation period in any other similar transaction overlaps with any Relevant Period or, if applicable, Settlement Valuation Period under this Master Confirmation as a result of any postponement of the Termination Date or extension of the
Settlement Valuation Period pursuant to “Valuation Disruption” above, Counterparty shall promptly amend such transaction to avoid any such overlap. 
 5. Regulatory Disruption. In the event that GS&Co. concludes, in good faith and in its commercially reasonable discretion, that it is appropriate with respect to any legal, regulatory or self-regulatory requirements or related
policies and procedures (whether or not such requirements, policies or procedures are imposed by law or have been voluntarily adopted by GS&Co.), for it to refrain from purchasing Shares on any Scheduled Trading Day or Days during the Hedge
Period, the Calculation Period or, if applicable, the Settlement Valuation Period, GS&Co. may by written notice to Counterparty elect to deem that a Market Disruption Event has occurred and will be continuing on such Scheduled Trading Day or
Days. 
 6. 10b5-1 Plan. 
 (a)
Counterparty represents, warrants and covenants to GS&Co. that Counterparty is entering into this Master Confirmation and each Transaction hereunder in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1 under
the Exchange Act (“Rule 10b5-1”) or any other antifraud or anti-manipulation provisions of the federal or applicable state securities laws and that it has not entered into or altered and will not enter into or alter any
corresponding or hedging transaction or position with respect to the Shares. It is the intent of the parties that each Transaction entered into under this Master Confirmation comply with the requirements of paragraphs (c)(1)(i)(A) and (B) of
Rule 10b5-1 and each Transaction entered into under this Master Confirmation shall be interpreted to comply with the requirements of Rule 10b5-1(c). 
 (b) Counterparty will not seek to control or influence GS&Co.’s decision to make any “purchases or sales” (within the meaning of Rule 10b5-1(c)(1)(i)(B)(3)) under any Transaction entered into under
this Master Confirmation, including, without limitation, GS&Co.’s decision to enter into any hedging transactions. Counterparty represents and warrants that it has consulted with its own advisors as to the legal aspects of its adoption and
implementation of this Master Confirmation, each Supplemental Confirmation and each Trade Notification under Rule 10b5-1. 
  

 9 

 (c) Counterparty acknowledges and agrees that any amendment, modification, waiver or termination of this
Master Confirmation, the relevant Supplemental Confirmation or Trade Notification must be effected in accordance with the requirements for the amendment or termination of a “plan” as defined in Rule 10b5-1(c). Without limiting the
generality of the foregoing, any such amendment, modification, waiver or termination shall be made in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5, and no such amendment, modification or waiver shall be made
at any time at which Counterparty or any officer, director, manager or similar person of Counterparty is aware of any material non-public information regarding Counterparty or the Shares. 
 7. Rule 10b-18. (a) Counterparty (or any “affiliated purchaser” as defined in Rule 10b-18 under the Exchange Act (“Rule 10b-18”))
shall not, without the prior written consent of GS&Co., directly or indirectly purchase any Shares (including by means of a derivative instrument), listed contracts on the Shares or securities that are convertible into, or exchangeable or
exercisable for Shares (including, without limitation, any Rule 10b-18 purchases of blocks (as defined in Rule 10b-18)) during any Relevant Period or, if applicable, Settlement Valuation Period, except through GS&Co; provided that
purchases effected by or for an issuer plan of Counterparty by an agent independent of the issuer within the meaning of Rule 10b-18(a)(13)(ii) shall not be subject to this Section 7(a). 
 (b) With respect to (i) all purchases of Shares made by GS&Co. during any relevant Hedge Period in respect of any Transaction and
(ii) purchases during the related Calculation Period (as defined above) of a number of Shares equal to the Minimum Shares for such Transaction less the number of Shares so purchased during the related Hedge Period in respect of such
Transaction, GS&Co. will use good faith efforts to effect such purchases in a manner so that, if such purchases were made by Counterparty, they would meet the requirements of Rule 10b-18(b)(2), (3) and (4) under the Exchange Act, and
effect calculations in respect thereof, taking into account any applicable Securities and Exchange Commission or staff no-action letters or interpretations as appropriate and subject to any delays between the execution and reporting of a trade of
the Shares on the Exchange and other circumstances beyond GS&Co.’s control. 
 8. Special Provisions for Merger Transactions. Notwithstanding
anything to the contrary herein or in the Equity Definitions: 
 (a) Counterparty agrees that it: 
 (i) will not during the period commencing on the Trade Date through the end of the Relevant Period or, if applicable, the Settlement
Valuation Period for any Transaction make, or permit to be made, any public announcement (as defined in Rule 165(f) under the Securities Act) of any Merger Transaction or potential Merger Transaction unless such public announcement is made prior to
the opening or after the close of the regular trading session on the Exchange for the Shares; 
 (ii) shall promptly (but in
any event prior to the next opening of the regular trading session on the Exchange) notify GS&Co. following any such announcement that such announcement has been made; and 
 (iii) shall promptly (but in any event prior to the next opening of the regular trading session on the Exchange) provide GS&Co. with
written notice specifying (i) Counterparty’s average daily Rule 10b-18 Purchases (as defined in Rule 10b-18) during the three full calendar months immediately preceding the announcement date that were not effected through GS&Co. or its
affiliates and (ii) the number of Shares purchased pursuant to the proviso in Rule 10b-18(b)(4) under the Exchange Act for the three full calendar months preceding the announcement date. Such written notice shall be deemed to be a certification
by Counterparty to GS&Co. that such information is true and correct. In addition, Counterparty shall promptly notify GS&Co. of the earlier to occur of the completion of such transaction and the completion of the vote by target shareholders.
Counterparty acknowledges that any such notice may cause the terms of any Transaction to be adjusted or such Transaction to be terminated; accordingly, Counterparty acknowledges that its delivery of such notice must comply with the standards set
forth in Section 6(c) above. 
 (b) In connection with a Merger Transaction, GS&Co. in good faith and its reasonable discretion may
(i) suspend the Hedge Period, the Calculation Period and/or any Settlement Valuation Period and postpone the Scheduled Termination Date of any Transaction and make related adjustments as if such event were a Potential 

  

 10 

 
Adjustment Event or (ii) treat the occurrence of such public announcement as an Additional Termination Event with Counterparty as the sole Affected
Party and the Transactions hereunder as the Affected Transactions and, for the avoidance of doubt, with the amount under Section 6(e) of the Agreement determined in a commercially reasonable manner taking into account the fact that the
Calculation Period or Settlement Valuation Period, as the case may be, had fewer Scheduled Trading Days than originally anticipated. 
 “Merger Transaction” means any merger, acquisition or similar transaction involving a recapitalization as contemplated by Rule 10b-18(a)(13)(iv) under the Exchange Act. For the avoidance of doubt, transactions in which the
consideration is solely cash and there is no valuation period shall not constitute “Merger Transactions” hereunder. 
 9. Special Provisions for
Friendly Transaction Announcements. (a) If a Friendly Transaction Announcement occurs on or prior to the Settlement Date for any Transaction, then the Number of Shares to be Delivered for such Transaction shall be determined as if the words
“less than the Minimum Shares and not” and “, but not below zero,” were deleted from the definition thereof. If a Friendly Transaction Announcement occurs after the Trade Date, but prior to the First Acceleration Date of any
Transaction, the First Acceleration Date shall be the date of such Friendly Transaction Announcement. If a Friendly Transaction Announcement occurs after the Settlement Date for any Transaction or any earlier date of termination or cancellation of
such Transaction pursuant to Section 6 of the Agreement or Article 12 of the Equity Definitions, then a second settlement of such Transaction (a “Second Settlement”) shall occur (notwithstanding such earlier termination or
cancellation) with a Number of Shares to be Delivered equal to the lesser of (i) zero and (ii) (x) the Number of Shares to be Delivered determined pursuant to the first sentence of this paragraph as if such Friendly Transaction
Announcement occurred prior to such Settlement Date minus (y) the Number of Shares to be Delivered determined pursuant to Section 1 of this Master Confirmation (provided that in the case of a Second Settlement occurring after such
an early termination or cancellation, a Number of Shares to be Delivered shall not be determined and instead a Forward Cash Settlement Amount will be determined as provided in Annex A). If the Number of Shares to be Delivered for any settlement of
any Transaction is a negative number, then the terms of the Counterparty Settlement Provisions in Annex A shall apply. 
 (b)
“Friendly Transaction Announcement” means (i) an Acquisition Transaction Announcement by Counterparty or its board of directors prior to the last day of the Relevant Period or any earlier date of termination or cancellation of
the relevant Transaction pursuant to Section 6 of the Agreement or Article 12 of the Equity Definitions (such date, the “Actual Termination Date”), (ii) an announcement by Counterparty or its board of directors prior to
the date three months following the Scheduled Termination Date that an Acquisition Transaction that is the subject of an Acquisition Transaction Announcement occurring prior to the Actual Termination Date has been approved, agreed to, recommended by
or otherwise consented to by Counterparty or its board of directors, or negotiated by Counterparty or any authorized representative of Counterparty, or (iii) where Counterparty or its board of directors has a legal obligation to make a
recommendation to its shareholders in respect of any such Acquisition Transaction contemplated by clause (i) or (ii) of this Section 9(b) prior to the date three months following the Scheduled Termination Date, the absence of a
recommendation that its shareholders reject such transaction. 
 (c) “Acquisition Transaction Announcement” means
(i) the announcement of an Acquisition Transaction, (ii) an announcement that Counterparty or any of its subsidiaries has entered into an agreement, a letter of intent or an understanding designed to result in an Acquisition Transaction,
(iii) the announcement of the intention to solicit or enter into, or to explore strategic alternatives or other similar undertaking that may include, an Acquisition Transaction, or (iv) any other announcement that in the reasonable
judgment of the Calculation Agent may result in an Acquisition Transaction. For the avoidance of doubt, announcements as used in the definition of Acquisition Transaction Announcement refer to any public announcement whether made by the Issuer or a
third party; provided that in the case of an Acquisition Transaction of the type described in clause (iv) of the definition thereof, such announcement shall not be an Acquisition Transaction Announcement with respect to a Transaction if
it occurs after the first 60 calendar days following the Trade Date for such Transaction. 
 (d) “Acquisition Transaction”
means (i) any Merger Event (for purposes of this definition the definition of Merger Event shall be read with the references therein to “100%” being replaced by “15%” and to “50%” by “75%” and without
reference to the clause beginning immediately following the definition of Reverse Merger therein to the end of such definition), Tender Offer or Merger Transaction or any other transaction involving the merger of Counterparty with or into any third
party, (ii) the sale or transfer of all or substantially all of the assets 

  

 11 

 
of Counterparty, (iii) a recapitalization, reclassification, binding share exchange or other similar transaction, (iv) any acquisition, lease,
exchange, transfer, disposition (including by way of spin-off or distribution) of assets (including any capital stock or other ownership interests in subsidiaries) or other similar event by Counterparty or any of its subsidiaries where the aggregate
consideration transferable or receivable by or to Counterparty or its subsidiaries exceeds 20% of the market capitalization of Counterparty and (v) any transaction in which Counterparty or its board of directors has a legal obligation to make a
recommendation to its shareholders in respect of such transaction (whether pursuant to Rule 14e-2 under the Exchange Act or otherwise). 
 10.
Acknowledgments. (a) The parties hereto intend for: 
 (i) each Transaction to be a “securities
contract” as defined in Section 741(7) of the Bankruptcy Code, a “swap agreement” as defined in Section 101(53B) of the Bankruptcy Code and a “forward contract” as defined in Section 101(25) of the Bankruptcy
Code, and the parties hereto to be entitled to the protections afforded by, among other Sections, Sections 362(b)(6), 362(b)(17), 362(b)(27), 362(o), 546(e), 546(g), 546(j), 555, 556, 560 and 561 of the Bankruptcy Code; 
 (ii) the Agreement to be a “master netting agreement” as defined in Section 101(38A) of the Bankruptcy Code; 
 (iii) a party’s right to liquidate, terminate or accelerate any Transaction, net out or offset termination values or payment amounts,
and to exercise any other remedies upon the occurrence of any Event of Default or Termination Event under the Agreement with respect to the other party or any Extraordinary Event that results in the termination or cancellation of any Transaction to
constitute a “contractual right” (as defined in the Bankruptcy Code); and 
 (iv) all payments for, under or in
connection with each Transaction, all payments for the Shares (including, for the avoidance of doubt, payment of the Prepayment Amount) and the transfer of such Shares to constitute “settlement payments” and “transfers” (as
defined in the Bankruptcy Code). 
 (b) Counterparty acknowledges that: 
 (i) during the term of any Transaction, GS&Co. and its affiliates may buy or sell Shares or other securities or buy or sell options or
futures contracts or enter into swaps or other derivative securities in order to establish or adjust its Hedge Position with respect to such Transaction; 
 (ii) GS&Co. and its affiliates may also be active in the market for the Shares other than in connection with hedging activities in relation to any Transaction; 
 (iii) GS&Co. shall make its own determination as to whether, when or in what manner any hedging or market activities in
Counterparty’s securities shall be conducted and shall do so in a manner that it deems appropriate to hedge its price and market risk with respect to the Forward Price and the VWAP Price; 
 (iv) any market activities of GS&Co. and its affiliates with respect to the Shares may affect the market price and volatility of the
Shares, as well as the Forward Price and VWAP Price, each in a manner that may be adverse to Counterparty; and 
 (v) each
Transaction is a derivatives transaction in which it has granted GS&Co. an option; GS&Co. may purchase shares for its own account at an average price that may be greater than, or less than, the price paid by Counterparty under the terms of
the related Transaction. 
 (c) Counterparty and GS&Co. acknowledge that none of Counterparty, GS&Co., or any of their respective
affiliates, intends to treat the payment of the Prepayment Amount by Counterparty to GS&Co. on the Prepayment Date with respect to any Transaction as a loan for purposes of filing any U.S. federal, state or local tax return. 
  

 12 

 11. Credit Support Documents. The parties hereto acknowledge that no Transaction hereunder is secured by any
collateral that would otherwise secure the obligations of Counterparty herein or pursuant to the Agreement. 
 12. Set-off. (a) The parties agree
to amend Section 6 of the Agreement by adding a new Section 6(f) thereto as follows: 
 “(f) Upon the occurrence of an Event of
Default or Termination Event with respect to a party who is the Defaulting Party or the Affected Party (“X”), the other party (“Y”) will have the right (but not be obliged) without prior notice to X or any other person to set-off
or apply any obligation of X owed to Y (or any Affiliate of Y) (whether or not matured or contingent and whether or not arising under the Agreement, and regardless of the currency, place of payment or booking office of the obligation) against any
obligation of Y (or any Affiliate of Y) owed to X (whether or not matured or contingent and whether or not arising under the Agreement, and regardless of the currency, place of payment or booking office of the obligation). Y will give notice to the
other party of any set-off effected under this Section 6(f). 
 Amounts (or the relevant portion of such amounts) subject to set-off may
be converted by Y into the Termination Currency at the rate of exchange at which such party would be able, acting in a reasonable manner and in good faith, to purchase the relevant amount of such currency. If any obligation is unascertained, Y may
in good faith estimate that obligation and set-off in respect of the estimate, subject to the relevant party accounting to the other when the obligation is ascertained. Nothing in this Section 6(f) shall be effective to create a charge or other
security interest. This Section 6(f) shall be without prejudice and in addition to any right of set-off, combination of accounts, lien or other right to which any party is at any time otherwise entitled (whether by operation of law, contract or
otherwise).” 
 (b) Notwithstanding anything to the contrary in the foregoing, GS&Co. agrees not to set off or net amounts due from
Counterparty with respect to any Transaction against amounts due from GS&Co. to Counterparty with respect to contracts or instruments that are not Equity Contracts. “Equity Contract” means any transaction or instrument that does
not convey to GS&Co. rights, or the ability to assert claims, that are senior to the rights and claims of common stockholders in the event of Counterparty’s bankruptcy. 
 13. Delivery of Shares. Notwithstanding anything to the contrary herein, GS&Co. may, by prior notice to Counterparty, satisfy its obligation to deliver any Shares or other securities on any date due (an
“Original Delivery Date”) by making separate deliveries of Shares or such securities, as the case may be, at more than one time on or prior to such Original Delivery Date, so long as the aggregate number of Shares and other
securities so delivered on or prior to such Original Delivery Date is equal to the number required to be delivered on such Original Delivery Date. 
 14.
Early Termination. In the event that an Early Termination Date (whether as a result of an Event of Default or a Termination Event) occurs or is designated with respect to any Transaction (except as a result of a Merger Event in which the
consideration or proceeds to be paid to holders of Shares consists solely of cash), if either party would owe any amount to the other party pursuant to Section 6(d)(ii) and 6(e) of the Agreement (any such amount, a “Payment
Amount”), then, in lieu of any payment of such Payment Amount, Counterparty may, no later than the Early Termination Date or the date on which such Transaction is terminated, elect to deliver or for GS&Co. to deliver, as the case may
be, to the other party a number of Shares (or, in the case of a Merger Event, a number of units, each comprising the number or amount of the securities or property that a hypothetical holder of one Share would receive in such Merger Event (each such
unit, an “Alternative Delivery Unit” and, the securities or property comprising such unit, “Alternative Delivery Property”)) with a value equal to the Payment Amount, as determined by the Calculation Agent (and the
parties agree that, in making such determination of value, the Calculation Agent may take into account a number of factors, including the market price of the Shares or Alternative Delivery Property on the date of early termination and, if such
delivery is made by GS&Co., the prices at which GS&Co. purchases 

  

 13 

 
Shares or Alternative Delivery Property to fulfill its delivery obligations under this Section 14); provided that in determining the composition
of any Alternative Delivery Unit, if the relevant Merger Event involves a choice of consideration to be received by holders, such holder shall be deemed to have elected to receive the maximum possible amount of cash. If such delivery is made by
Counterparty, paragraphs 2 through 7 of Annex A shall apply as if such delivery were a settlement of the Transaction to which Net Share Settlement applied, the Cash Settlement Payment Date were the Early Termination Date and the Forward Cash
Settlement Amount were zero (0) minus the Payment Amount owed by Counterparty. In no event, however, shall the number of Shares required to be delivered by Counterparty pursuant to this Master Confirmation be greater than the Reserved
Shares (as defined in the Annex A). 
 15. Calculations and Payment Date upon Early Termination. The parties acknowledge and agree that in calculating
Loss pursuant to Section 6 of the Agreement GS&Co. may (but need not) determine losses without reference to actual losses incurred but based on expected losses assuming a commercially reasonable (including without limitation with regard to
reasonable legal and regulatory guidelines) risk bid were used to determine loss to avoid awaiting the delay associated with closing out any hedge or related trading position in a commercially reasonable manner prior to or sooner following the
designation of an Early Termination Date. Notwithstanding anything to the contrary in Section 6(d)(ii) of the Agreement, all amounts calculated as being due in respect of an Early Termination Date under Section 6(e) of the Agreement will
be payable on the day that notice of the amount payable is effective; provided that if Counterparty elects to receive Shares or Alternative Delivery Property in accordance with Section 14, such Shares or Alternative Delivery Property
shall be delivered on a date selected by GS&Co. as promptly as practicable in a commercially reasonable manner. 
 16. Special Provisions for
Counterparty Payments. The parties hereby agree that, notwithstanding anything to the contrary herein or in the Agreement, in the event that an Early Termination Date (whether as a result of an Event of Default or a Termination Event) occurs or
is designated with respect to any Transaction and, as a result, Counterparty owes to GS&Co. an amount calculated under Section 6(e) of the Agreement, such amount shall be deemed to be zero; provided that following a Friendly
Transaction Announcement, this Section 16 shall cease to apply. 
 17. Delivery of Cash. For the avoidance of doubt, nothing in this Master
Confirmation shall be interpreted as requiring Counterparty to deliver cash in respect of the settlement of the Transactions contemplated by this Master Confirmation following payment by Counterparty of the relevant Prepayment Amount, except in
circumstances where the required cash settlement thereof is permitted for classification of the contract as equity by EITF 00-19 as in effect on the relevant Trade Date (including, without limitation, where Counterparty so elects to deliver cash or
fails timely to elect to deliver Shares or Alternative Delivery Property in respect of the settlement of such Transactions). 
 18. Agreements in Respect
of Termination Amounts. Notwithstanding any provision of this Master Confirmation, any Supplemental Confirmation, the Agreement or the Equity Definitions to the contrary, in determining any amounts payable in respect of the termination or
cancellation of any Transaction pursuant to Section 6 of the Agreement, Article 12 of the Equity Definitions or Section 14 of this Master Confirmation, the Calculation Agent shall make such determination without regard to changes in
dividends (including, without limitation, Extraordinary Dividends) stock loan rates, liquidity or hedging costs. 
 19. Agreement in Respect of
Adjustments. Notwithstanding any provision of this Master Confirmation, any Supplemental Confirmation, the Agreement or the Equity Definitions to the contrary, the Calculation Agent shall not make any adjustment in respect of any Transaction
pursuant to Article 11 or Article 12 of the Equity Definitions or pursuant to this Master Confirmation to account for changes in dividends (including, without limitation, Extraordinary Dividends), stock loan rate, liquidity or hedging costs.

 20. Explanations Provided. As soon as reasonably practicable upon request after any calculation, adjustment or determination with respect to any
Transaction hereunder the Calculation Agent (or GS&Co., as applicable, if making any calculation, adjustment or determination expressly provided in this Master Confirmation to be made by GS&Co.) shall provide to Counterparty a reasonably
detailed explanation of such calculation, adjustment or determination. 
  

 14 

 21. Claim in Bankruptcy. GS&Co. acknowledges and agrees that this Confirmation is not intended to convey to it
rights with respect to the Transaction that are senior to the claims of common stockholders in the event of Counterparty’s bankruptcy. 
 22. General
Obligations Law of New York. With respect to each Transaction, (i) this Master Confirmation, together with the related Supplemental Confirmation, as supplemented by the related Trade Notification, is a “qualified financial
contract”, as such term is defined in Section 5-701(b)(2) of the General Obligations Law of New York (the “General Obligations Law”); (ii) such Trade Notification constitutes a “confirmation in writing sufficient
to indicate that a contract has been made between the parties” hereto, as set forth in Section 5-701(b)(3)(b) of the General Obligations Law; and (iii) this Master Confirmation, together with the related Supplemental Confirmation,
constitutes a prior “written contract” as set forth in Section 5-701(b)(1)(b) of the General Obligations Law, and each party hereto intends and agrees to be bound by this Master Confirmation and the related Supplemental Confirmation,
as supplemented by the Trade Notification. 
 23. Governing Law. The Agreement, this Master Confirmation, each Supplemental Confirmation, each Trade
Notification and all matters arising in connection with the Agreement, this Master Confirmation, each Supplemental Confirmation and each Trade Notification shall be governed by, and construed and enforced in accordance with, the laws of the State of
New York (without reference to its choice of laws doctrine other than Title 14 of Article 5 of the New York General Obligations Law). 
 24. Offices.

 (a) The Office of GS&Co. for each Transaction is: One New York Plaza, New York, New York 10004. 
 (b) The Office of Counterparty for each Transaction is: 333 Lakeside Drive, Foster City, California 94404. 
 25. Arbitration. The Agreement, this Master Confirmation, each Supplemental Confirmation and each Trade Notification are subject to the following
arbitration provisions: 
 (a) All parties to this Confirmation are giving up the right to sue each other in court, including the
right to a trial by jury, except as provided by the rules of the arbitration forum in which a claim is filed. 
 (b) Arbitration
awards are generally final and binding; a party’s ability to have a court reverse or modify an arbitration award is very limited. 
 (c) The ability of the parties to obtain documents, witness statements and other discovery is generally more limited in arbitration than in court proceedings. 
 (d) The arbitrators do not have to explain the reason(s) for their award. 
 (e) The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry, unless
Counterparty is a member of the organization sponsoring the arbitration facility, in which case all arbitrators may be affiliated with the securities industry. 
 (f) The rules of some arbitration forums may impose time limits for bringing a claim in arbitration. In some cases, a claim that is ineligible for arbitration may be brought in court. 
 (g) The rules of the arbitration forum in which the claim is filed, and any amendments thereto, shall be incorporated into this Master Confirmation.

 Counterparty agrees that any and all controversies that may arise between Counterparty and GS&Co., including, but not limited
to, those arising out of or relating to the Agreement or any Transaction hereunder, shall be determined by arbitration conducted before The New York Stock Exchange, Inc. 

  

 15 

 
(“NYSE”) or NASD Dispute Resolution (“NASD-DR”), or, if the NYSE and NASD-DR decline to hear the matter, before the American
Arbitration Association, in accordance with their arbitration rules then in force. The award of the arbitrator shall be final, and judgment upon the award rendered may be entered in any court, state or federal, having jurisdiction. 

No person shall bring a putative or certified class action to arbitration, nor seek to enforce any pre-dispute arbitration agreement against any
person who has initiated in court a putative class action or who is a member of a putative class who has not opted out of the class with respect to any claims encompassed by the putative class action until: (i) the class certification is
denied; (ii) the class is decertified; or (iii) Counterparty is excluded from the class by the court. 
 Such forbearance to
enforce an agreement to arbitrate shall not constitute a waiver of any rights under this Master Confirmation except to the extent stated herein. 
 26.
Counterparts. This Master Confirmation may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Master Confirmation by signing and delivering one or more
counterparts. 
  

 16 

 EXECUTION COPY 
 Counterparty hereby agrees (a) to check this Master Confirmation carefully and immediately upon receipt so that errors or discrepancies can be promptly identified and rectified and (b) to confirm that the
foregoing (in the exact form provided by GS&Co.) correctly sets forth the terms of the agreement between GS&Co. and Counterparty with respect to any particular Transaction to which this Master Confirmation relates, by manually signing this
Master Confirmation or this page hereof as evidence of agreement to such terms and providing the other information requested herein and immediately returning an executed copy to Equity Derivatives Documentation Department, Facsimile
No. 212-428-1980/83. 
  

			
	Yours faithfully,
	
	GOLDMAN, SACHS & CO.
		
	By:	 	/s/ David Goldenberg
		 	Authorized Signatory
		 	David Goldenberg, Vice President

  

					
	Agreed and Accepted By:
	
	GILEAD SCIENCES, INC.
		
	By:	 	/s/ John F. Milligan, Ph.D.
		 	Name:	 	John F. Milligan, Ph.D.
		 	Title:	 	Chief Operating Officer and Chief Financial Officer

 SCHEDULE A 
 SUPPLEMENTAL CONFIRMATION 
  

			
	To:	  	 Gilead Sciences, Inc.
 333 Lakeside Drive
 Foster City, CA 94404

		
	From:	  	Goldman, Sachs & Co.
		
	Subject:	  	Collared Accelerated Stock Buyback
		
	Ref. No:	  	[Insert Reference No.]
		
	Date:	  	[Insert Date]

 The purpose of this Supplemental Confirmation is to confirm the terms and conditions of the
Transaction entered into between Goldman, Sachs & Co. (“GS&Co.”) and Gilead Sciences, Inc. (“Counterparty”) (together, the “Contracting Parties”) on the Trade Date specified below. This
Supplemental Confirmation is a binding contract between GS&Co. and Counterparty as of the relevant Trade Date for the Transaction referenced below. 
 1.
This Supplemental Confirmation supplements, forms part of, and is subject to the Master Confirmation dated as of February 29, 2008 (the “Master Confirmation”) between the Contracting Parties, as amended and supplemented from
time to time. All provisions contained in the Master Confirmation govern this Supplemental Confirmation except as expressly modified below. 
 2. The terms
of the Transaction to which this Supplemental Confirmation relates are as follows: 
  

			
	Trade Date:	  	[            ]
		
	Forward Price Adjustment Amount:	  	USD [        ]
		
	Hedge Period End Date:	  	[                ]
		
	 Scheduled Termination Date:
	  	[                ]
		
	 First Acceleration Date:
	  	[                ]
		
	 Prepayment Amount:
	  	USD [                ]
		
	 Prepayment Date:
	  	[            ]
		
	 Initial Shares:
	  	[                ] Shares
		
	 Initial Share Delivery Date:
	  	[            ]
		
	 Minimum Shares:
	  	As set forth in the Trade Notification, to be a number of Shares equal to (a) the Prepayment Amount divided by (b) [ ]% of the Hedge Period Reference Price.
		
	 Maximum Shares:
	  	As set forth in the Trade Notification, to be a number of Shares equal to (a) the Prepayment Amount divided by (b) [ ]% of the Hedge Period Reference Price.

  

 A-1 

			
	Additional Relevant Days:	  	The 10 Exchange Business Days immediately following
the Termination Date.

 3. Counterparty represents and warrants to GS&Co. that neither it nor any “affiliated purchaser” (as
defined in Rule 10b-18 under the Exchange Act) has made any purchases of blocks pursuant to the proviso in Rule 10b-18(b)(4) under the Exchange Act during either (i) the four full calendar weeks immediately preceding the Trade Date or
(ii) during the calendar week in which the Trade Date occurs. 
 4. This Supplemental Confirmation may be executed in any number of counterparts, all of
which shall constitute one and the same instrument, and any party hereto may execute this Supplemental Confirmation by signing and delivering one or more counterparts. 
  

 A-2 

 Counterparty hereby agrees (a) to check this Supplemental Confirmation carefully and immediately
upon receipt so that errors or discrepancies can be promptly identified and rectified and (b) to confirm that the foregoing (in the exact form provided by GS&Co.) correctly sets forth the terms of the agreement between GS&Co. and
Counterparty with respect to the Transaction to which this Supplemental Confirmation relates, by manually signing this Supplemental Confirmation or this page hereof as evidence of agreement to such terms and providing the other information requested
herein and immediately returning an executed copy to Equity Derivatives Documentation Department, facsimile No. 212-428-1980/83. 
  

			
	Yours sincerely,
	
	GOLDMAN, SACHS & CO.
		
	By:	 	 
		 	Authorized Signatory

  

			
	Agreed and Accepted By:
	
	GILEAD SCIENCES, INC.
		
	By:	 	 
		 	Name:
		 	Title:

  

 A-3 

 SCHEDULE B 
 TRADE NOTIFICATION 
  

			
	To:	  	 Gilead Sciences, Inc.
 333 Lakeside Drive
 Foster City, CA 94404

		
	From:	  	Goldman, Sachs & Co.
		
	Subject:	  	Collared Accelerated Stock Buyback
		
	Ref. No:	  	[Insert Reference No.]
		
	Date:	  	[Insert Date]

 The purpose of this Trade Notification is to notify you of certain terms in the Transaction
entered into between Goldman, Sachs & Co. (“GS&Co.”) and Gilead Sciences, Inc. (“Counterparty”) (together, the “Contracting Parties”) on the Trade Date specified below. 
 This Trade Notification supplements, forms part of, and is subject to the Supplemental Confirmation dated as of [Insert Date of Supplemental
Confirmation] (the “Supplemental Confirmation”) between the Contracting Parties, as amended and supplemented from time to time. The Supplemental Confirmation is subject to the Master Confirmation dated as of February 29,
2008 (the “Master Confirmation”) between the Contracting Parties, as amended and supplemented from time to time. 
  

			
	Hedge Completion Date:	  	[            ]
		
	Calculation Period Start Date:	  	[            ]
		
	Hedge Period Reference Price:	  	USD [            ]
		
	Minimum Shares:	  	[        ]
		
	Maximum Shares:	  	[        ]

  

			
	Yours sincerely,
	
	GOLDMAN, SACHS & CO.
		
	By:	 	 
		 	Authorized Signatory

  

 B-1 

 ANNEX A 
 COUNTERPARTY SETTLEMENT PROVISIONS 
 1. The following Counterparty Settlement Provisions shall apply to the
extent indicated under the Master Confirmation: 
  

			
	Settlement Currency:	  	USD
		
	Settlement Method Election:	  	Applicable; provided that (i) Section 7.1 of the Equity Definitions is hereby amended by deleting the word “Physical” in the sixth line thereof and replacing it with the
words “Net Share” and (ii) the Electing Party may make a settlement method election only if the Electing Party represents and warrants to GS&Co. in writing on the date it notifies GS&Co. of its election that, as of such date, the
Electing Party is not aware of any material non-public information concerning Counterparty or the Shares and is electing the settlement method in good faith and not as part of a plan or scheme to evade compliance with the federal securities laws.

		
	Electing Party:	  	Counterparty
		
	Settlement Method	  	
	Election Date:	  	The Termination Date; provided that if GS&Co. accelerates the Termination Date pursuant to the proviso to the definition of “Termination Date,” the Settlement Method
Election Date shall be the second Exchange Business Day immediately following the Termination Date, and the latest time for making such Settlement Method Election shall be 10 minutes prior to the open of trading on the Exchange on such second
Exchange Business Day; and provided further that if a Friendly Transaction Announcement occurs after the Settlement Date, the Settlement Method Election Date for the Second Settlement shall be the date of the Friendly Transaction
Announcement.
		
	Default Settlement Method:	  	Cash Settlement
		
	Forward Cash Settlement	  	
	Amount:	  	The Number of Shares to be Delivered multiplied by the Settlement Price; provided that in the case of a Second Settlement occurring after an early termination or cancellation of
the relevant Transaction pursuant to Section 6 of the Agreement or Article 12 of the Equity Definitions, the Forward Cash Settlement Amount shall equal the lesser of (i) zero and (ii)(x) the Payment Amount that would have been calculated for
such early termination or cancellation if the words “less than the Minimum Shares and not” and “,but not below zero,” had been deleted from the definition of Number of Shares to be Delivered and, for purposes of “Special
Provisions for Counterparty Payments” of the Master Confirmation, the relevant Friendly Transaction Announcement had occurred prior to such calculation, as determined by the Calculation Agent (with an amount that would have been owed by
Counterparty expressed as a negative number for purposes of this calculation) minus (y) the actual Payment Amount calculated for such early termination or cancellation.

  

 1 

			
	Settlement Price:	  	The average of the VWAP Prices (or, in the case of a
Second Settlement, the Relevant Prices) for the Exchange
Business Days in the Settlement Valuation Period, subject
to
Valuation Disruption as specified in the Master
Confirmation or, in the case of a Second Settlement,
subject to Section 6.6(a) of the Equity Definitions as if
such dates were Valuation Dates.
		
	Settlement Valuation Period:	  	A number of Scheduled Trading Days, not to exceed 30, selected by GS&Co. in its discretion, beginning on the Scheduled Trading Day immediately following the Termination Date or, in the case
of a Second Settlement, the date of the Friendly Transaction Announcement; provided that GS&Co. may determine a higher number of Scheduled Trading Days as it shall determine in good faith and in a commercially reasonable manner to be
appropriate in light of legal or regulatory considerations.
		
	Cash Settlement:	  	If Cash Settlement is applicable, then Buyer shall pay to Seller the absolute value of the Forward Cash Settlement Amount on the Cash Settlement Payment Date.
		
	Cash Settlement	  	
	Payment Date:	  	The date one Settlement Cycle following the last day of the Settlement Valuation Period.
		
	Net Share Settlement	  	
	Procedures:	  	If Net Share Settlement is applicable, Net Share Settlement shall be made in accordance with paragraphs 2 through 7 below.

 2. Net Share Settlement shall be made by delivery on the Cash Settlement Payment Date of a number
of Shares satisfying the conditions set forth in paragraph 3 below (the “Registered Settlement Shares”), or a number of Shares not satisfying such conditions (the “Unregistered Settlement Shares”), in either case
with a value equal to the absolute value of the Forward Cash Settlement Amount, with such Shares’ value based on the value thereof to GS&Co. (which value shall, in the case of Unregistered Settlement Shares, take into account a commercially
reasonable illiquidity discount), in each case as determined by the Calculation Agent. 
 3. Counterparty may only deliver Registered
Settlement Shares pursuant to paragraph 2 above if: 
 (a) a registration statement covering public resale of the Registered Settlement
Shares by GS&Co. and any other underwriter(s) (the “Registration Statement”) shall have been filed with the Securities and Exchange Commission under the Securities Act and been declared or otherwise become effective on or prior
to the date of delivery, and no stop order shall be in effect with respect to the Registration Statement; a printed prospectus relating to the Registered Settlement Shares (including any prospectus supplement thereto, the
“Prospectus”) shall have been delivered to GS&Co. and any other underwriter(s), in such quantities as GS&Co. shall reasonably have requested, on or prior to the date of delivery; 
  

 2 

 (b) the form and content of the Registration Statement and the Prospectus (including, without limitation,
any sections describing the plan of distribution) shall be reasonably satisfactory to GS&Co.; 
 (c) as of or prior to the date of
delivery, GS&Co. and its agents shall have been afforded a reasonable opportunity to conduct a due diligence investigation with respect to Counterparty customary in scope for underwritten offerings of equity securities of similar size, as
determined by GS&Co. in its good faith and commercially reasonable discretion, taking into account market conditions prevailing at that time and conditions and nature of Counterparty at that time (including, without limitation, if deemed
appropriate by GS&Co., the right to have made available to them for inspection all financial and other records, pertinent corporate documents and other information reasonably requested by them), and the results of such investigation are
satisfactory to GS&Co., in its commercially reasonable discretion; and 
 (d) as of the date of delivery, an agreement (the
“Underwriting Agreement”) shall have been entered into with GS&Co. and any other underwriter(s) in connection with the public resale of the Registered Settlement Shares by GS&Co. and any other underwriter(s) substantially
similar to underwriting agreements customary for underwritten offerings of equity securities of similar size, in form and substance reasonably satisfactory to GS&Co., which Underwriting Agreement shall include, without limitation, provisions
substantially similar to those contained in such underwriting agreements relating, without limitation, to the indemnification of, and contribution in connection with the liability of, GS&Co. and its affiliates and the provision of customary
opinions, accountants’ comfort letters and lawyers’ negative assurance letters. 
 4. If Counterparty delivers Unregistered
Settlement Shares pursuant to paragraph 2 above, then Counterparty covenants as follows: 
 (a) all Unregistered Settlement Shares shall be
delivered to GS&Co. (or any affiliate of GS&Co. designated by GS&Co.) and any other initial purchaser(s) pursuant to the exemption from the registration requirements of the Securities Act provided by Section 4(2) thereof;

 (b) as of or prior to the date of delivery, GS&Co. and any other initial purchaser(s) and any potential purchaser of any such shares
from GS&Co. (or any affiliate of GS&Co. designated by GS&Co.) or from any other initial purchaser(s) identified by GS&Co. shall be afforded a commercially reasonable opportunity to conduct a due diligence investigation with respect
to Counterparty customary in scope for private placements of equity securities of similar size, as determined by GS&Co. in its good faith and commercially reasonable discretion, taking into account market conditions prevailing at that time and
conditions and nature of Counterparty at that time (including, without limitation, if deemed appropriate by GS&Co., the right to have made available to them for inspection all financial and other records, pertinent corporate documents and other
information reasonably requested by them); 
 (c) as of the date of delivery, Counterparty shall enter into an agreement (a “Private
Placement Agreement”) with GS&Co. (or any affiliate of GS&Co. designated by GS&Co.) and any other initial purchaser(s) in connection with the private placement of such shares by Counterparty to GS&Co. (or any such affiliate)
and any other initial purchaser(s) and the private resale of such shares by GS&Co. (or any such affiliate) and any other initial purchaser(s), substantially similar to private placement purchase agreements customary for private placements of
equity securities of similar size, in form and substance satisfactory to GS&Co. in its good faith and commercially reasonable discretion, which Private Placement Agreement shall include, without limitation, provisions substantially similar to
those contained in such private placement purchase agreements relating, without limitation, to the indemnification of, and contribution in connection with the liability of, GS&Co. and its affiliates and any other initial purchaser(s) and the
provision of customary opinions, accountants’ comfort letters and lawyers’ negative assurance letters, and shall provide for the payment by Counterparty of all commercially reasonable fees and expenses in connection with such resale,
including all commercially reasonable fees and expenses of counsel for GS&Co. and any other initial purchaser(s), and shall contain representations, warranties, covenants and agreements of Counterparty reasonably necessary or advisable to
establish and maintain the availability of an exemption from the registration requirements of the Securities Act for such resales; and 
  

 3 

 (d) in connection with the private placement of such shares by Counterparty to GS&Co. (or any such
affiliate) and any other initial purchaser(s) and the private resale of such shares by GS&Co. (or any such affiliate) and any other initial purchaser(s), Counterparty shall, if so requested by GS&Co. in its good faith and commercially
reasonable discretion, prepare, in cooperation with GS&Co., a customary private placement memorandum in form and substance reasonably satisfactory to GS&Co. and any other initial purchaser(s). 
 5. GS&Co., itself or through an affiliate (the “Selling Agent”) or any underwriter(s), will sell all, or such lesser portion as may
be required hereunder, of the Registered Settlement Shares or Unregistered Settlement Shares and any Makewhole Shares (as defined below) (together, the “Settlement Shares”) delivered by Counterparty to GS&Co. pursuant to
paragraph 6 below commencing on the Cash Settlement Payment Date and continuing until the date on which the aggregate Net Proceeds (as such term is defined below) of such sales, as determined by GS&Co., is equal to the absolute value of the
Forward Cash Settlement Amount (such date, the “Final Resale Date”). If the proceeds of any sale(s) made by GS&Co., the Selling Agent or any underwriter(s), net of any fees and commissions (including, without limitation,
underwriting or placement fees) customary for similar transactions under the circumstances at the time of the offering, together with carrying charges and expenses incurred in connection with the offer and sale of the Shares (including, but without
limitation to, the covering of any over-allotment or short position (syndicate or otherwise)) (the “Net Proceeds”) exceed the absolute value of the Forward Cash Settlement Amount, GS&Co. will refund, in USD, such excess to
Counterparty on the date that is three (3) Currency Business Days following the Final Resale Date, and, if any portion of the Settlement Shares remains unsold, GS&Co. shall return to Counterparty on that date such unsold Shares. 

6. If the Calculation Agent determines that the Net Proceeds received from the sale of the Registered Settlement Shares or Unregistered Settlement
Shares or any Makewhole Shares, if any, pursuant to this paragraph 6 are less than the absolute value of the Forward Cash Settlement Amount (the amount in USD by which the Net Proceeds are less than the absolute value of the Forward Cash Settlement
Amount being the “Shortfall” and the date on which such determination is made, the “Deficiency Determination Date”), Counterparty shall on the Exchange Business Day next succeeding the Deficiency Determination Date
(the “Makewhole Notice Date”) deliver to GS&Co., through the Selling Agent, a notice of Counterparty’s election that Counterparty shall either (i) pay an amount in cash equal to the Shortfall on the day that is one
(1) Currency Business Day after the Makewhole Notice Date, or (ii) deliver additional Shares. If Counterparty elects to deliver to GS&Co. additional Shares, then Counterparty shall deliver additional Shares in compliance with the terms
and conditions of paragraph 3 or paragraph 4 above, as the case may be (the “Makewhole Shares”), on the first Clearance System Business Day which is also an Exchange Business Day following the Makewhole Notice Date in such number as
the Calculation Agent reasonably believes would have a market value on that Exchange Business Day equal to the Shortfall. Such Makewhole Shares shall be sold by GS&Co. and any other underwriter(s) or initial purchaser(s) in accordance with the
provisions above; provided that if the sum of the Net Proceeds from the sale of the originally delivered Shares and the Net Proceeds from the sale of any Makewhole Shares is less than the absolute value of the Forward Cash Settlement Amount
then Counterparty shall, at its election, either make such cash payment or deliver to GS&Co. further Makewhole Shares until such Shortfall has been reduced to zero. 
 7. Notwithstanding the foregoing, in no event shall the aggregate number of Settlement Shares and Makewhole Shares be greater than the Reserved Shares minus the amount of any Shares actually delivered by
Counterparty under any other Transaction(s) under this Master Confirmation (the result of such calculation, the “Capped Number”). Counterparty represents and warrants (which shall be deemed to be repeated on each day that a
Transaction is outstanding) that the Capped Number is equal to or less than the number of Shares determined according to the following formula: 
 A – B 
  

			
	Where	  	A = the number of authorized but unissued shares of the Counterparty that are not reserved for future
issuance on the date of the determination of the Capped Number; and
		
		  	B = the maximum number of Shares required to be delivered to third parties if Counterparty elected Net Share Settlement of all transactions in the Shares (other than Transactions in the Shares
under this Master Confirmation) with all third parties that are then currently outstanding and unexercised.

 “Reserved Shares” means initially, 23,000,000 Shares. The Reserved Shares may be
increased or decreased in a Supplemental Confirmation. 
  

 4 

 SUPPLEMENTAL CONFIRMATION 
  

			
	To:	  	 Gilead Sciences, Inc.
 333 Lakeside Drive
 Foster City, CA 94404

		
	From:	  	Goldman, Sachs & Co.
		
	Subject:	  	Collared Accelerated Stock Buyback
		
	Ref. No:	  	SDB1626953575
		
	Date:	  	February 29, 2008

 The purpose of this Supplemental Confirmation is to confirm the terms and conditions of the
Transaction entered into between Goldman, Sachs & Co. (“GS&Co.”) and Gilead Sciences, Inc. (“Counterparty”) (together, the “Contracting Parties”) on the Trade Date specified below. This
Supplemental Confirmation is a binding contract between GS&Co. and Counterparty as of the relevant Trade Date for the Transaction referenced below. 
 1. This Supplemental Confirmation supplements, forms part of, and is subject to the Master Confirmation dated as of February 29, 2008 (the “Master Confirmation”) between the Contracting Parties, as amended and
supplemented from time to time. All provisions contained in the Master Confirmation govern this Supplemental Confirmation except as expressly modified below. 
 2. The terms of the Transaction to which this Supplemental Confirmation relates are as follows: 
  

			
	Trade Date:	  	February 29, 2008
		
	Forward Price Adjustment Amount:	  	USD 0.24
		
	Hedge Period End Date:	  	March 7, 2008
		
	Scheduled Termination Date:	  	June 25, 2008
		
	First Acceleration Date:	  	April 7, 2008
		
	Prepayment Amount:	  	USD 500,000,000
		
	Prepayment Date:	  	March 5, 2008
		
	Initial Shares:	  	7,204,334 Shares
		
	Initial Share Delivery Date:	  	March 5, 2008
		
	Minimum Shares:	  	As set forth in the Trade Notification, to be a number of Shares equal to (a) the Prepayment Amount divided by (b) 110% of the Hedge Period Reference Price.
		
	Maximum Shares:	  	As set forth in the Trade Notification, to be a number of Shares equal to (a) the Prepayment Amount divided by (b) 90% of the Hedge Period Reference Price.
		
	Additional Relevant Days:	  	The 10 Exchange Business Days immediately following the Termination Date.

  

 1 

 3. Counterparty represents and warrants to GS&Co. that neither it nor any “affiliated purchaser” (as
defined in Rule 10b-18 under the Exchange Act) has made any purchases of blocks pursuant to the proviso in Rule 10b-18(b)(4) under the Exchange Act during either (i) the four full calendar weeks immediately preceding the Trade Date or
(ii) during the calendar week in which the Trade Date occurs. 
 4. This Supplemental Confirmation may be executed in any number of counterparts, all of
which shall constitute one and the same instrument, and any party hereto may execute this Supplemental Confirmation by signing and delivering one or more counterparts. 
  

 2 

 Counterparty hereby agrees (a) to check this Supplemental Confirmation carefully and immediately
upon receipt so that errors or discrepancies can be promptly identified and rectified and (b) to confirm that the foregoing (in the exact form provided by GS&Co.) correctly sets forth the terms of the agreement between GS&Co. and
Counterparty with respect to the Transaction to which this Supplemental Confirmation relates, by manually signing this Supplemental Confirmation or this page hereof as evidence of agreement to such terms and providing the other information requested
herein and immediately returning an executed copy to Equity Derivatives Documentation Department, facsimile No. 212-428-1980/83. 
  

			
	Yours sincerely,
	
	GOLDMAN, SACHS & CO.
		
	By:	 	/s/ David Goldenberg
		 	Authorized Signatory
		 	David Goldenberg, Vice President

  

					
	Agreed and Accepted By:
	
	GILEAD SCIENCES, INC.
		
	By:	 	/s/ John F. Milligan, Ph.D.
		 	Name:	 	John F. Milligan, Ph.D.
		 	Title:	 	Chief Operating Officer and Chief Financial OfficerTenofovir Disoproxil Fumarate Manufacturing Supply Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 Exhibit 10.62 
 GILEAD SCIENCES LIMITED.-AMPAC FINE CHEMICALS LLC 
 TENOFOVIR DISOPROXIL FUMARATE MANUFACTURING
SUPPLY AGREEMENT 
 THE PARTIES HEREBY ACKNOWLEDGE AND AGREE
THE FOLLOWING: 
 THIS SUPPLY AGREEMENT (“Agreement”) is entered into as of March 6, 2008
(“Effective Date”), by and between Ampac Fine Chemicals LLC, a California limited liability company (“AFC”) having its principal place of business at Highway 50 & Hazel Avenue, Rancho Cordova, CA 95670, and
a mailing address of P.O. Box 1718, Rancho Cordova, CA 95741, and Gilead Sciences Limited, an Irish limited company (“GSL”), having its principal place of business at Unit 13, Stillorgan Industrial Park, Blackrock, Co. Dublin,
Ireland. AFC and GSL may be referred to individually as a “Party” and collectively as the “Parties” in this Agreement. 
 WHEREAS, AFC is a known manufacturer of active pharmaceutical ingredients with expertise in cGMP manufacturing, and GSL and its designees manufacture and market pharmaceutical products for human use. 
 WHEREAS, AFC and GSL desire to establish mutually agreeable terms for the commercial supply of bulk tenofovir disoproxil fumarate
(“Product”) as an active pharmaceutical ingredient by AFC to GSL. 
 NOW, THEREFORE, in consideration of (i) AFC’s
agreement to manufacture and supply Product to GSL for the monetary amounts set forth in this Agreement; (ii) the promises, covenants, agreements and other valuable consideration hereinafter set forth, and intending to be legally bound, the
Parties hereby: 
 1. AGREEMENT ACCEPTANCE: AFC has read and understands these terms and conditions set forth in this Agreement (these
“terms”) and understands that AFC’s written acceptance or delivery of any Product under these terms shall constitute AFC’s acceptance of these terms. All terms and conditions proposed by AFC which are different from or in
addition to these terms and are not agreed to in writing by GSL are expressly rejected by GSL, and shall not become a part of these terms. GSL has read and understands these terms and shall purchase the Product manufactured by AFC and pay for the
supply of the Product in accordance with the terms and provisions of these terms. Any modifications to these terms shall, prior to their implementation, be mutually agreed upon by the Parties hereto and shall be made in accordance with
Section 28. 
 Neither the General Sales Conditions of AFC nor the General Purchase Conditions of GSL shall apply to the supply of the Product by AFC to
GSL pursuant to these terms. 
 2. TERM: The term of this Agreement shall begin as of the Effective Date, and shall remain in effect until
December 31, 2010 (the “Initial Term”) unless earlier terminated according to Section 13 “Termination” of this Agreement. 
  

 Page 1 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 3. SUPPLY: During the term of this Agreement, AFC will manufacture Product for GSL for use in manufacture of
Finished Product (as defined in Section 4 below). During the term of this Agreement, AFC is obligated to manufacture Product at the location and in the quantities set forth herein. AFC will not manufacture or supply Product to any person or
entity other than GSL without GSL’s prior written consent. 
  

	 	a)	Facility: AFC will manufacture the Product for GSL only at its facility located at Rancho Cordova, CA, or such other facilities as the Parties agree to in writing
(collectively, the “Facility”). GSL has inspected the Facility and has acknowledged, based upon information in its possession as of the Effective Date, that the Facility appears to be appropriate for the purposes of manufacturing
the Products. 

  

	 	b)	Minimum Quantities: During the Initial Term and any renewal term GSL will purchase and AFC will deliver at least the quantities of Product set forth in Exhibit A. Failure in
any year by GSL to purchase the required quantities will result in [*] an amount equal to the [*], the invoice for which will be [*], and such invoice shall be [*]. For clarity, Regulatory
Terminations (as defined in Section 13(c) below) shall not be deemed to be breaches of GSL’s obligations under this Section 3(b). 

  

	 	c)	Forecasting: Prior to [*] of [*], GSL shall provide to AFC a [*] for the [*]. Such Purchase Order shall detail the
[*], and shall be [*]. 

  

	 	d)	Acceptance: AFC will respond in writing to each purchase order received from GSL (“GSL Purchase Order”) within [*] calendar days of receipt.
The response shall include AFC’s inability to comply with, or confirmation of the delivery dates and quantities set forth in the GSL Purchase Order. 

  

	 	e)	Failure to Supply: If AFC is unable to supply sufficient quantities of the Product to meet its minimum obligations under Section 3(b), or should either Party perceive
that a shortfall in delivery of Product by AFC is likely to occur for any reason, the Parties will [*] GSL will have the right [*] or [*]. Any quantities [*] to meet such a shortfall shall be
[*]. If GSL must [*] AFC shall be liable for [*]. Repeated shortfalls may be considered a material breach of this Agreement, as described in Section 13 of this Agreement. 

  

	 	f)	Delay: If release and/or shipment of any quantity is delayed after AFC has accepted an order, through the fault of AFC, by more than [*] days [*]
[*] the quantity shall be considered a shortfall, and treated as above in Section 3(e). If such delay is caused by the fault of GSL, GSL will make [*] to remediate the fault [*] however, after
[*] days from the date of expected release and/or shipment, AFC shall be entitled to issue the relevant invoice(s) in any case. 

 4. GOOD MANUFACTURING PRACTICES: AFC expressly warrants that all Product covered by these terms have been manufactured in accordance with current good manufacturing practices (“cGMP”) as established by the United
States Food and Drug Administration (the “FDA”) for the manufacture of pharmaceutical materials, as well as other applicable rules and regulations of the FDA and other governmental or regulatory agencies of United States or other
countries where finished products of GSL incorporating the Product (collectively, the “Finished Products”) are marketed with jurisdiction over the manufacture, use, or sale of Product, as then in effect. Each party shall promptly
notify the other of any new 

  

 Page 2 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 
instructions or specifications required by the FDA, the Federal Food, Drug and Cosmetic Act, the Federal Public Health Service Act or other applicable
regulations of the United States and/or other countries where the Finished Products are marketed, and shall confer with each other with respect to the best means to comply with such requirements and shall allocate any costs of implementing such
changes on an equitable basis. Upon written request of GSL, AFC will permit representatives of GSL to observe such manufacture, or any government inspection of AFC’s manufacturing process for the Products covered by these terms, at mutually
agreeable times and AFC shall permit GSL to inspect copies of AFC’s manufacturing records, including its batch records, for the purposes of assuring product quality and compliance with agreed-upon manufacturing procedures. 
 5. MANUFACTURING PROCESS: GSL shall make available to AFC, [*] all such know-how, information, and technical assistance if needed by AFC so as to
allow AFC to manufacture Product with utmost efficiency and to the standard of GSL as will be more precisely described by GSL in writing to AFC before the start of manufacturing of the Product. AFC shall manufacture the Product in conformance with
the relevant specifications, as then in effect (the “Specifications”) and according to the manufacturing process description as set forth in the Gilead Sciences Tenofovir DF Contract Manufacturing Manual dated June 6, 2000, and
as thereafter amended (the “Contract Manufacturing Manual”). 
 6. RAW MATERIALS: Raw materials used in the manufacture of Product
will conform to the specifications set forth in the Contract Manufacturing Manual (the “Raw Material Specifications”) and such conformance will be verified in accordance with the testing standards and procedures specified therein.
AFC agrees that it will facilitate changes to the Raw Material Specifications that are necessary or appropriate in light of FDA or other regulatory requirements. AFC shall not be liable hereunder if the raw materials meet the Raw Material
Specifications and the Product fails to meet the Specifications because the Raw Material Specifications are inadequate. 
 7. CHANGE IN MANUFACTURING
PROCESS: AFC shall obtain GSL’s prior written approval, per the Notification Policy (October 5, 2001), before implementing any planned change in the materials, equipment, process, or procedures used to manufacture the Product that would
constitute a major change under cGMP, or that would constitute noncompliance with the manufacturing process set forth in the Contract Manufacturing Manual. AFC shall disclose all proposed changes in such manufacturing materials, equipment, process,
or procedure to GSL at a level sufficient to allow GSL to practice such changed manufacturing process. GSL shall notify AFC of any change in the materials, equipment, process, analytical methods, specifications, or procedures to be used in the
manufacture of the Product in writing, by means of timely updates to the Contract Manufacturing Manual, identical copies of which reside at AFC and GSL. AFC shall provide GSL with an authentic copy of the current master batch record for the
preparation of the Product. The cost of implementing any amendment or change of whatever nature to the procedures described in the Contract Manufacturing Manual, as well as any extra costs resulting from the implementation of such change, shall be
borne by [*]. However, the Parties recognize the pricing agreed in Exhibit A reflect implementation of the process developed by AFC and GSL during 2007-2008, which, at the time of this agreement, is not represented in the Contract
Manufacturing Manual. 
  

 Page 3 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 8. PROCESS IMPROVEMENTS: 
  

	 	a)	[*] agrees to communicate to [*] any idea and substantial improvement made by [*] arising from [*] under the following
conditions: (i) all rights and title to improvements (patented or unpatentable) which are related to the [*] shall be assigned to [*] which shall have only the right to utilize such improvements in the manufacture of
the Product; (ii) all rights and title to improvements (patented or unpatentable) which apply to the [*] and provided that [*] is not contained in said improvements, shall be assigned to [*] which shall
have only the right to utilize such improvements in the process of the Product; (iii) a royalty-free worldwide exclusive license [*] shall be granted by [*] to [*] for improvements (patented or
unpatentable) related to said processing [*] (iv) in the event that [*] contracts out the manufacture of the Product to any third party, any improvement made by [*] hereunder may be disclosed to such
contract manufacturer but rights to use the same shall be restricted to the manufacture of the Product and the Parties hereto will [*]. 

  

	 	b)	The Parties recognize the process changes under development by AFC and GSL for piloting and validation in 2008. All rights to said improvement shall be passed to [*]
in accordance with the provisions of Section 8(a), (i) through (iii), above. The Parties confirm no further remuneration shall be sought by [*] under Section 8(a)(iv) above. AFC will produce a development report
describing such revised process to be provided to GSL prior to commercial scale validation of such process. Further, AFC shall provide to GSL necessary assistance in support of technology transfer to one Gilead Sciences, Inc.-owned facility, which
may include teleconferences, meetings, and chemistry support during the initial commercial campaign. 

 9. QUALITY CONTROL SAMPLE AND
DOCUMENTATION: Manufacture of the Product shall at all times be in strict conformance with the Specifications and such conformance will be verified in accordance with the testing procedures, specified herein. Prior to the delivery of any batch
of Product, AFC shall provide GSL with (i) a quality control sample of such batch to be held by GSL for analytical reference, (ii) written confirmation that the batch records for such batch have been reviewed and approved by AFC’s
quality assurance unit (Certificate of Compliance), and (iii) a Certificate of Analysis confirming that such batch meets Specifications. No delivery of the Product shall be made until GSL accepts the material in accordance with the provisions
of Paragraph 10. 
 10. BATCH ACCEPTANCE AND REJECTION: GSL shall have the right without penalty to cancel delivery of an entire batch of
Product at any time within [*] days after receipt of the applicable Certificate of Compliance and Certificate of Analysis (the “Acceptance Period”). Title and risk of loss for each batch of Product shall pass to GSL upon
[*]. If no such notice of rejection is received, GSL shall be deemed to have accepted the batch of Product upon the expiration of Acceptance Period. Either GSL’s written acceptance of the batch or expiration of the Acceptance
Period shall result in GSL assuming title and risk of loss for related batch. AFC shall be authorized to make delivery of the full batch upon GSL’s acceptance of the batch, pending receipt of specific delivery instructions from GSL. AFC
represents and warrants that the Product delivered to the destination specified by GSL shall comply with the Specifications for 

  

 Page 4 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 
the Product. Any contestation of the quantity of Product delivered to the destination specified by GSL or the related documentation must be made in
writing to AFC within [*] days from receipt thereof by GSL or an agent of GSL. GSL and AFC shall [*] or [*] as appropriate. After notice of rejection is given, GSL shall cooperate with AFC in determining
whether rejection is necessary or justified. AFC will evaluate process issues and other reasons for such non-compliance. AFC shall notify GSL as promptly as reasonably possible whether it accepts GSL’s basis for any rejection. In the event that
such contestation of quality by GSL is not accepted by AFC, a sample of the contested batch sealed by AFC in compliance with applicable regulations shall be submitted by AFC to an independent laboratory, acceptable to GSL, and the check assay of
said laboratory shall be accepted by the two Parties as final and binding. The cost of said analysis made by the laboratory shall be borne by the failing party. Whether or not AFC accepts GSL’s basis for rejection, AFC shall use reasonable
efforts at GSL’s request to replace such rejected Product. If the third party laboratory determines that the batch meets the Specifications, GSL guarantees to purchase that batch at the agreed-upon price, irrespective of whether AFC has already
replaced it. GSL may not destroy any batch of Product until it receives written notification from AFC that AFC does not dispute that the batch fails to meet Specifications and that AFC does not request return of the Product. Upon authorization from
AFC to do so, GSL shall destroy the Product received in the rejected delivery promptly at AFC’s cost and provide AFC with certification of such destruction. GSL shall, upon receipt of AFC’s request for return, promptly return said Product
or quality control sample to AFC, at AFC’s cost. At its election, GSL may treat any rejected batch of Product as [*], until and unless it is finally determined that the batch complied with the warranties in Section 14. 

 11. QUANTITY AND PRICE: The quantity, schedule, and purchase price of Product covered by these terms will be provided in separate GSL Purchase
Orders. These terms shall apply to all GSL Purchase Orders written while these terms are in effect. All GSL Purchase Orders covered by this agreement shall reference this agreement by its effective date. The negotiated price for the Product shall
include up to [*] storage at AFC’s facility, according to Paragraph 25. 
 12. DELIVERY, SHIPPING, BILLING AND PAYMENT: GSL
will provide AFC with an estimated delivery date for each batch at the end of the Acceptance Period or at the time of acceptance of the batch, if earlier. GSL will then have [*] days to schedule processing of the Product with its
contracted formulation and encapsulation facility and provide specific delivery instructions to AFC. If specific delivery instructions are not provided to AFC within the [*] day period, the “Warehousing” provision included
under Paragraph 25 will be considered in effect and GSL will have [*] days to provide the written request and other information required to be provided to AFC under that provision. AFC will package and load the Product in accordance
with AFC’s customary practices for pharmaceutical compounds, unless otherwise specified by GSL. Unless otherwise agreed to by the Parties in writing, all shipments shall be shipped [*] pursuant to written instructions provided by
GSL to AFC. The quantity of Product made available to GSL’s carrier shall be the same amount as invoiced by AFC, unless AFC is otherwise directed in writing by GSL. AFC shall maintain appropriate insurance as far as AFC’s custodial
responsibilities with respect to the Product temporarily held at AFC’s facility and owned by GSL. [*] is responsible for selecting the carrier that will transport the Product. GSL will maintain the appropriate insurance coverage
for Product that it has accepted, including any 

  

 Page 5 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 
Product owned by GSL held temporarily or stored at AFC’s facility. Within [*] calendar days of receipt of such shipping instructions from
GSL, AFC shall ship the invoiced amount of Product to its destination. All invoices from AFC to GSL covering Product shipped to GSL shall be stated, and all payments to AFC by GSL shall be made, in [*]. The invoices will be issued upon
completion of the batches and issuance of the Certificate of Compliance and Certificate of Analysis for each batch in accordance with Section 9. AFC’s invoice shall be paid by GSL not later than [*] days following the
latest of (i) the receipt of the applicable invoice, (ii) expiration of the Acceptance Period, and (iii) the receipt of the Certificate of Analysis and Certificate of Compliance. Any invoiced amount which is not paid within
[*] days of its due date shall be assessed a late payment fee at a rate of [*] or the maximum rate permitted by applicable law with respect to such obligations, whichever is less. 
 13. TERMINATION: 
  

	 	a)	Either Party may terminate this Agreement for a material breach by the other Party. A material breach may be encountered if either Party: (a) repudiates or breaches a
[*] of this Agreement; or (b) fails to perform payments or services or deliver goods as provided in this Agreement. A Party may terminate this Agreement under this Section 13 by giving the breaching Party written notice,
specifying the circumstances of the breach, including the provisions of this Agreement that are breached (“Notice”). The breaching Party, if such a breach has indeed occurred, has [*] calendar days from receipt of such
Notice to cure such breach of this Agreement. 

 If the breach has not been cured at the end of the [*] day period
or if the breaching Party is not making [*] to cure such breach, then, upon immediate Notice to the breaching Party, the breaching Party shall be in default and the nonbreaching Party may terminate this Agreement. If the breaching
Party is making [*] to cure such breach up until the end of the [*] day period, the breaching Party shall be granted an additional [*] day period to cure said breach so long as it continues to use
[*] to cure such breach. Unless the termination is on the grounds of a material breach resulting [*], GSL will purchase raw material and intermediates [*]. Otherwise, GSL shall have the right, but not the
obligation, to purchase such raw materials, intermediates and inventories of the Product pursuant to Section 6 as GSL may determine in its sole discretion. For clarity, but without limitation on other contract damages that may be available in
the event of a material breach by a party, in the event the termination is on grounds of a material breach resulting [*] during the Initial Term, GSL shall pay to AFC [*]. 
  

	 	b)	If either Party becomes bankrupt, the other Party may, with immediate Notice to the first Party, terminate the Agreement with no liabilities whatsoever, subject to relevant
legislation and provisions herein contained. 

  

	 	c)	GSL may terminate this Agreement in whole or in part at any time by giving [*] days written notice to AFC, if GSL, in its sole discretion, determines that
[*] or if any the FDA or any other regulatory agency of applicable jurisdiction access (“Regulatory Authority”) [*] (each, a “Regulatory Termination”). GSL may terminate this Agreement if
any Regulatory Authority that regulates Product or Finished Product [*] or [*]. Should GSL terminate this Agreement by a Regulatory Termination: 

  

	 	(i)	AFC will take reasonable measures to cease any ongoing production and limit further expenses associated with such ongoing production; 

  

 Page 6 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

	 	(ii)	GSL will purchase raw material and intermediates at AFC’s [*] of this Agreement, and will [*] and 

  

	 	(iii)	AFC will use commercially reasonable efforts to [*] under this Agreement; and 

  

	 	d)	Except as otherwise set forth in this Agreement, termination of this Agreement shall not release any Party hereto from any payment, liability or other obligation existing at the
date of termination. 

 14. LIMITED WARRANTY: AFC warrants that Product delivered hereunder will (i) be manufactured by AFC in
accordance with cGMP and other applicable FDA and other rules and regulations of the United States or other countries where Finished Products are marketed, (ii) be manufactured in accordance with the agreed-upon manufacturing procedures
described in the master batch records supplied to GSL in accordance with the provisions of Section 7, as may be modified and disclosed to GSL in accordance with the provisions of Section 7, (iii) conform to the applicable
Specifications set forth in the Contract Manufacturing Manual at the time of Product delivery, and (iv) be provided in compliance with all applicable laws and regulations as more fully set forth in Section 4 above. GSL’s remedies and
AFC’s liability with respect to this warranty are set forth below. This warranty is the only warranty made by AFC with respect to Product delivered hereunder, and may only be modified or amended by a written instrument signed by a duly
authorized officer of AFC and accepted by GSL. THE EXPRESS WARRANTIES SET FORTH IN Section 4 AND THIS Section 14 ARE THE EXCLUSIVE WARRANTIES HEREUNDER, IN LIEU OF ALL OTHER EXPRESS OR IMPLIED WARRANTIES, INCLUDING, WITHOUT LIMITATION, THE
WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 15. INDEMNIFICATION BY BUYER: GSL agrees to indemnify, hold harmless, and
defend AFC and AFC’s directors, officers, employees and agents, and the directors, officers, employees and agents of any AFC parent, subsidiary, or related company (the “AFC Indemnitees”) from and against any and all claims, suits,
losses, damages, costs, fees, and expenses including without limiting those resulting from or arising out of the [*] or resulting from or arising out of possession, use, transformation, or sale of the Product by any person other than a
AFC Indemnitee, including without limiting the generality of the foregoing any damages, losses, or liabilities whatsoever with respect to death or injury to person or damage to property, provided that AFC provides GSL with prompt notice of any such
claim and the exclusive ability to defend (with the reasonable cooperation of AFC) or settle any such claim, except to the extent that such claims, suits, losses, damages, costs, fees, or expenses arise or result from any negligent or
wrongful act or omission of AFC or any AFC Indemnitee. 
  

 Page 7 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 16. INDEMNIFICATION BY SELLER: AFC agrees to indemnify, hold harmless and defend GSL and GSL’s directors,
officers, employees and agents, and the directors, officers, employees and agents of any GSL parent, subsidiary, or related company (the “GSL Indemnitees”) from and against any and all claims, suits, losses, damages, costs, reasonable
fees, and expenses resulting from or arising out of its manufacture of the Product, or the transportation, storage or use of the Product by AFC before expiration of the Acceptance Period or GSL’s acceptance of the Product, if earlier, including
without limiting the generality of the foregoing any damages, losses, or liabilities whatsoever with respect to death or injury to person or damage to property, provided that GSL provides AFC with prompt notice of any such claim and the exclusive
ability to defend (with the reasonable cooperation of GSL) or settle any such claim, except to the extent that such claims, suits, losses, damages, costs, fees, or expenses arises or results from any negligent or wrongful act or omission of
GSL or any GSL Indemnitee. 
 17. RECALLS AND ADVERSE EVENTS: If there is a recall or there are adverse events for Product that may be related to the
processing, manufacture or testing of Product by AFC, AFC will provide at GSL’s cost any assistance reasonably requested by GSL in connection with such recall or adverse events. If Product is recalled due to a breach of the warranty in
Section 14, AFC shall be responsible for out-of-pocket expenses reasonably incurred in connection with such recall or seizure including loss of Finished Product, notification, transportation, destruction expenses and replacement costs,
[*] In any event, [*]. 
 18. NONDISCLOSURE: No right, express or implied, is granted by this agreement to either party to
use in any manner the name of the other or any other trade name or trademark of the other in connection with the performance of the work covered by this agreement. In addition, each party hereto shall act as an independent contractor and nothing in
this agreement shall be construed as to give either party the authority to act for, bind, or commit the other party in any way whatsoever. 
 19.
INDEPENDENT CONTRACTORS: Each Party hereto will act as an independent contractor and nothing in this Agreement shall be construed as to give either Party the authority to act for, bind, or commit the other Party in any way whatsoever.

 20. FORCE MAJEURE: Neither party shall be liable for failure to perform or for delay in performing any of its obligations under this agreement, if
such failure or delay is caused by labor disputes, lack of supply of materials through no fault of such party, an act of God, riot, fire, explosion, flood, hostilities of war, executive legislation or administrative order, or other conditions
reasonably beyond the control of such party, provided that the party experiencing the delay promptly notifies the other party of the delay. In the event of such cause intervening, this agreement shall be and remain suspended provided that if such
cause shall continue for a period of [*], the party not subject to the force majeure may [*] from the date of expiration of such period, [*]. 
 21. REMEDIES: The rights and remedies reserved to GSL in this agreement shall be cumulative, and in addition to all other or further remedies provided in law or equity. 
  

 Page 8 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 22. NONASSIGNABILITY: Neither party may assign or transfer this agreement or any rights or obligations
hereunder without the prior written consent of the other party, except that GSL may make such an assignment or transfer without AFC’s consent if such assignment or transfer is to an Affiliate or successor to substantially all of the business of
GSL, whether in a merger, sale of stock, sale of assets, or other similar transaction. Any assignment or transfer or attempted assignment or transfer by either party in violation of the terms of this Section 22 shall be null and void and of no
legal effect. In the case of any permitted assignment or transfer of or under this agreement, this agreement shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators, and assigns of the
Parties hereto. 
 23. GOVERNING LAW: This agreement is to be construed according to the laws of the State of [*] as such laws are
applied to contracts made in [*] between [*] residents, and excluding the United Nations’ Convention on Contracts for the Sale of Goods. 
 24. SEVERABILITY: In the event any term of this agreement is held to be invalid or unenforceable under any statute, regulation, ordinance, executive agreement or other rule of law, such term shall be deemed
modified or deleted, but only to the extent necessary to comply with such statute, regulation, ordinance, agreement or rule, and the valid or enforceable portion thereof and the remaining terms of this agreement will remain in full force and effect,
unless the invalid or unenforceable provisions are of such essential importance to this agreement that it is reasonably assumed that the Parties would not have entered into this agreement without the invalid terms. 
 25. WAREHOUSING: Subject to the availability of space and storage conditions, AFC will store Product for GSL upon written request by GSL no later than
[*] days after GSL’s receipt of the Certificate of Compliance and Certificate of Analysis. GSL’s written request must state that GSL requests AFC not to ship the Product, the business reason for delay and also provide an
estimated revised delivery date for the Product. The payment terms included in Section 12 are unchanged. GSL agrees to pay AFC storage charges for the Product at prevailing rates for the storage of similar Products under similar conditions.
However, the negotiated price of the Product includes storage of the Product for up to [*] at AFC’s facility [*] to GSL. For Product stored by AFC for GSL, delivery of Product will be considered to have occurred when
the Product is placed into storage by AFC. The provisions of Section 10 related to transfer of title and risk of loss for the Product remain in effect. AFC will store the Product in accordance with cGMP and other applicable FDA and other rules
and regulations of the United States. AFC will store Product segregated from other stored items in such a condition that Product is “ready to ship” with minimal delay. Product in storage at AFC will be shipped to GSL on a first-in,
first-out (FIFO) basis. [*] shall maintain appropriate insurance as far as AFC’s custodial responsibilities with respect to the Product owned by GSL and stored at AFC’s facility. Upon GSL’s written request, AFC will
provide GSL with a certificate of insurance verifying that AFC maintains appropriate insurance as far as AFC’s custodial responsibilities with respect to Product owned by GSL and stored at AFC’s facility. Upon AFC’s written request,
GSL will provide AFC with a certificate of insurance verifying that GSL maintains property insurance for Product that it owns that is stored at AFC’s facility. Upon GSL’s written request, AFC will remove a representative sample from any
Product owned by GSL and stored at AFC’s facility and forward that sample to GSL. 
  

 Page 9 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 26. NOTICES: All notices under this Agreement shall be in writing and shall be delivered personally, sent for
next day delivery by internationally recognized courier service or transmitted by facsimile (transmission confirmed), with confirmation by next day delivery by an internationally recognized courier service, to the following addresses and facsimiles
of the respective Parties or such other address or facsimile as is notified pursuant to this Section 26: 
  

			
	If to GSL:	  	With a copy to:
		
	 Gilead Sciences Limited/
 [*]
	  	 Gilead Sciences, Inc.
 333 Lakeside Drive
 Foster City, CA 94404
 USA
 Attention: Director, Chemical Manufacturing
 Facsimile: +[*]

		
	If to AFC:	  	With a copy to:
		
	 Ampac Fine Chemicals/
 [*] 
	  	 Ampac Fine Chemicals LLC
 Highway 50 & Hazel Avenue

 Rancho Cordova, CA 95670
 USA
 Attention: Vice President, Product Management
 Facsimile: +[*]

 27. CONFIDENTIALITY: 
  

	 	a)	 “Confidential Information” means with respect to GSL confidential or proprietary information of GSL or any of its Affiliates either disclosed in
oral, written or other tangible form or otherwise learned by AFC from GSL related to the manufacture of Product under (i) these terms and any purchase order related thereto, (ii) the Tenofovir DF Purchase Order Terms and Conditions dated
as of June 12, 2002 and August 9, 2007, as amended, and any purchase order related thereto, and (iii) the Gilead Sciences, Inc. Confidential Disclosure Agreement dated March 4, 2000 (collectively, the
“Documents”) that should reasonably be believed to be confidential or proprietary to GSL or any of its Affiliates, including but not limited to information directly related to the Product or the research, development, preclinical
and clinical programs, data and results; pharmaceutical or biologic candidates and products; inventions, works of authorship, trade secrets, processes, conceptions, formulas, patents, patent applications, and licenses; inventions; business, product,
marketing, sales, scientific and technical strategies, programs and results, including costs and prices; suppliers, manufacturers, customers, market data, personnel, and consultants of GSL or any of its Affiliates; and other confidential or
proprietary matters directly related to GSL or any of its Affiliates, including work done under any purchase order. “Confidential Information” means with respect to AFC any information which is not Confidential Information of GSL
and is confidential or proprietary information of AFC or any of its Affiliates or customers either disclosed in 

  

 Page 10 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

	 	 
oral, written or other tangible form or otherwise learned by GSL from AFC that should reasonably be believed to be confidential or proprietary to AFC or any
of its customers or Affiliates, including but not limited to information directly related to the contract manufacturing business of AFC; works of authorship, trade secrets, processes, conceptions, formulas, patents, patent applications, and
licenses; inventions; business, product, marketing, sales, scientific and technical strategies, programs and results, including costs and prices; suppliers, customers, market data, personnel, and consultants of AFC or any of its Affiliates; and
other confidential or proprietary matters directly related to AFC or any of its Affiliates, including work done by AFC for other customers. 

  

	 	b)	“Discloser” shall mean the party, whether GSL or AFC, disclosing its Confidential Information to the other party. “Recipient” shall mean the party,
whether GSL or AFC, receiving Confidential Information of the other party. 

  

	 	c)	“Affiliate” shall mean any corporation or other business entity controlled by, controlling, or under common control with the respective party. For this purpose,
“control” of a party, corporation or other business entity (including controlled by, controlling, or under common control with) shall mean the following (i) direct or indirect ownership or control of at least 50% of the issued and
voting capital by the respective party, or (ii) possession of the power to direct or cause the direction of the management and policies of an entity, whether by ownership of voting stock, by contract, or otherwise. 

  

	 	d)	Subject to Section 27(f), until [*], Recipient: 

  

	 	(i)	shall not use Confidential Information of Discloser except for the purpose of carrying out obligations contemplated by the Documents; 

  

	 	(ii)	will hold Confidential Information of Discloser in strictest confidence and shall not disclose Confidential Information of Discloser to third parties, except for its employees or
agents who require Confidential Information of Discloser in order to carry out obligations under the Documents and who are subject to binding obligations of confidentiality and restricted use at least as protective as those of this Section 27;

  

	 	(iii)	will protect the confidentiality of Confidential Information of Discloser using at least the same level of efforts and measures used to protect its own confidential information, and
at least commercially reasonable efforts and measures, including without limitation limiting access to Confidential Information commensurate with carrying out obligations contemplated by the Documents and keeping adequate records of those with
access to Confidential Information of Discloser and of all uses or dispositions of Confidential Information of Discloser; and 

  

	 	(iv)	will notify Discloser as promptly as practicable of any unauthorized use or disclosure of Confidential Information by employees or agents of which Recipient becomes aware.

  

 Page 11 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

	 	e)	Recipient’s obligations under Section 27(d) shall not apply to any Confidential Information that: 

  

	 	(i)	Recipient knew prior to learning it under the Documents, as demonstrated by written records predating the date it was learned under the Documents; 

  

	 	(ii)	is now, or becomes in the future, publicly available other than by an act or omission of Discloser; 

  

	 	(iii)	a third party discloses to Recipient, without any confidentiality obligations, and without any breach of any direct or indirect obligation of confidentiality to Discloser, as shown
by Recipient’s written records contemporaneous with such third party disclosure; or 

  

	 	(iv)	Recipient independently develops without use of or reference to Confidential Information of Discloser, as demonstrated by Recipient’s independent written records
contemporaneous with such development. 

  

	 	f)	Notwithstanding other provisions of this Section 27, Recipient may disclose Confidential Information of Discloser to the extent and to the persons or entities required under
applicable governmental law, rule, regulation or order, provided that Recipient (i) first gives prompt written notice of such disclosure requirement to Discloser so as to enable Discloser to seek any limitations on or exemptions from such
disclosure requirement and (ii) reasonably cooperates at Discloser’s request and expense in any such efforts by Discloser. 

  

	 	g)	Upon termination of these terms or Discloser’s request for any reason, Recipient will (i) immediately cease all use of all Confidential Information of Discloser disclosed
hereunder or under the other Documents and (ii) promptly return to Discloser or, if instructed by Discloser, destroy all such Confidential Information of Discloser, including any copies, extracts, summaries, or derivative works containing such
Confidential Information of Discloser, and certify in writing to Discloser the completion of such return and/or destruction, provided, however, that Recipient may retain one copy in its legal archives solely for the purpose of monitoring its
surviving obligations under the Documents. 

  

	 	h)	Discloser retains all right, title and interest in and to Confidential Information except to the extent otherwise provided by Section 8. This Section 27 gives Recipient no
right or license, by implication or otherwise, to any Confidential Information of Discloser or any intellectual property or other rights owned by or licensed to Discloser except the right to use Confidential Information solely for performance of
obligations under the Documents and as otherwise specifically provided in Section 8. Recipient may freely transfer, disclose and/or use Recipient’s Confidential Information for its or others’ purposes. 

  

 Page 12 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

	 	i)	Recipient acknowledges that any actual or threatened breach of this Section 27 may cause Discloser immediate and irreparable harm that cannot be adequately compensated by
monetary damages, and it therefore agrees that Discloser shall not be required to demonstrate irreparable harm in order to seek or obtain injunctive relief for actual or threatened breach of these terms. In addition to any injunctive relief,
Discloser may seek any other remedies available to it at law or in equity. 

 28. ENTIRE AGREEMENT; AMENDMENTS: This agreement together
with the attachments, exhibits, or supplements specifically referenced in this agreement, constitutes the entire, final, complete, and exclusive agreement between the Parties and supersedes all previous agreements (including specifically the
Tenofovir DF Purchase Order Terms and Conditions dated June 12, 2002, as amended by Amendment No. 1 and Amendment No. 2, the Tenofovir DF purchase order terms and conditions dated August 9, 2007 (CD-07-0200), and the Gilead
Sciences, Inc. Confidential Disclosure Agreement dated March 4, 2002)) or representations, written or oral, with respect to the subject matter of this agreement. This agreement may not be modified, amended, waived, discharged, or terminated
orally, but only by an instrument in writing signed by a duly authorized representative of each party. SUBJECT TO SUCH AMENDMENT, THE TERMS AND CONDITIONS SET FORTH HEREIN CONSTITUTE THE FINAL COMPLETE, EXCLUSIVE, AND ENTIRE AGREEMENT BETWEEN GSL
AND AFC WITH RESPECT TO THE SUBJECT MATTER HEREOF. ANY TERM OR CONDITION IN ANY AGREEMENT, CONFIRMATION, OR OTHER DOCUMENT FURNISHED BY GSL OR AFC WHICH IS IN ANY WAY INCONSISTENT WITH THE TERMS SET FORTH HEREIN IS HEREBY EXPRESSLY REJECTED.

 29. INSURANCE: Each Party will maintain at is own cost insurance policies, which may be by means of self-insurance, with respect to its activities
and obligations under this Agreement that are commercially reasonable as to terms, coverage and coverage limits in view of the scope of such Party’s activities and obligations under this Agreement. [*] At the other Party’s
request, each Party will supply certificates of insurance evidencing such coverages. 
 30. SURVIVAL: The provisions of Sections 8, 14, 15, 16, 17,
18, 22, 23, 24, and 27 shall survive the termination or expiration of this Agreement. 
  

 Page 13 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 The Parties have entered into this Agreement as of the Effective Date by their duly authorized representatives.

  

			
	GILEAD SCIENCES LIMITED
		
	By:	 	/s/ John F. Milligan
	Name:	 	John F. Milligan, Ph.D.
	Date:	 	March 4, 2008
	Title:	 	Director
	
	AMPAC FINE CHEMICALS LLC
		
	By:	 	/s/ Richard Beatty
	Name:	 	Richard Beatty
	Date:	 	March 6, 2008
	Title:	 	Vice President

  

 Page 14 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
  

 Exhibit A 
 Product Minimum Purchase Quantities 
 The table below sets forth GSL’s minimum Product purchase obligations for the stated calendar
years for Product for commercial use. 
 CASE A: 
  

					
	 Calendar Year
	 	 Minimum GSL Purchase
	 	Price ($USD/kg)
	2008	 	[*] MetricTons	 	[*]
	2009	 	[*] MetricTons	 	[*]
	2010	 	[*] MetricTons	 	[*]

 However, in the case that [*], the purchase obligations shall be: 
 CASE B: 
  

					
	 Calendar Year
	 	 Minimum GSL Purchase
	 	Price ($USD/kg)
	2008	 	[*] MetricTons	 	[*]
	2009	 	[*] MetricTons	 	[*]
	2010	 	[*] MetricTons	 	[*]

 In the event the Parties are operating in Case B, the minimum will be shifted to Case A after [*].

 Price shall be based upon the expected acquisition costs of the key raw materials below. Variance from these acquisitions costs shall be invoiced or
credited to GSL as [*]. 
  

					
	 Key Raw Material
	 	2008 Acquisition Cost Base
($USD/kg)	 	2009/2010 Acquisition Cost
Base ($USD/kg)
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]

 If, at any time, the [*], GSL shall [*]. [*] shall be considered in the
negotiations for 2011 and later deliveries. 
  

 Page 15 
 CD-08-0029 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]